iAVPs-ResBi: Identifying antiviral peptides by using deep residual network and bidirectional gated recurrent unit

Xinyan Ma; Yunyun Liang; Shengli Zhang; Xinyan Ma; Yunyun Liang; Shengli Zhang

doi:10.3934/mbe.2023954

Mathematical Biosciences and Engineering

2023, Volume 20, Issue 12: 21563-21587. doi: 10.3934/mbe.2023954

Previous Article Next Article

Research article

iAVPs-ResBi: Identifying antiviral peptides by using deep residual network and bidirectional gated recurrent unit

1.
School of Science, Xi'an Polytechnic University, Xi'an 710048, China
2.
School of Mathematics and Statistics, Xidian University, Xi'an 710071, China

Academic Editor: Vladimir Mityushev

Received: 25 September 2023 Revised: 15 November 2023 Accepted: 30 November 2023 Published: 05 December 2023

Human history is also the history of the fight against viral diseases. From the eradication of viruses to coexistence, advances in biomedicine have led to a more objective understanding of viruses and a corresponding increase in the tools and methods to combat them. More recently, antiviral peptides (AVPs) have been discovered, which due to their superior advantages, have achieved great impact as antiviral drugs. Therefore, it is very necessary to develop a prediction model to accurately identify AVPs. In this paper, we develop the iAVPs-ResBi model using k-spaced amino acid pairs (KSAAP), encoding based on grouped weight (EBGW), enhanced grouped amino acid composition (EGAAC) based on the N5C5 sequence, composition, transition and distribution (CTD) based on physicochemical properties for multi-feature extraction. Then we adopt bidirectional long short-term memory (BiLSTM) to fuse features for obtaining the most differentiated information from multiple original feature sets. Finally, the deep model is built by combining improved residual network and bidirectional gated recurrent unit (BiGRU) to perform classification. The results obtained are better than those of the existing methods, and the accuracies are 95.07, 98.07, 94.29 and 97.50% on the four datasets, which show that iAVPs-ResBi can be used as an effective tool for the identification of antiviral peptides. The datasets and codes are freely available at https://github.com/yunyunliang88/iAVPs-ResBi.

Keywords:

Citation: Xinyan Ma, Yunyun Liang, Shengli Zhang. iAVPs-ResBi: Identifying antiviral peptides by using deep residual network and bidirectional gated recurrent unit[J]. Mathematical Biosciences and Engineering, 2023, 20(12): 21563-21587. doi: 10.3934/mbe.2023954

Related Papers:

[1]	Abeer Alshareef . Quantitative analysis of a fractional order of the $SEI_{c}\, I_{\eta} VR$ epidemic model with vaccination strategy. AIMS Mathematics, 2024, 9(3): 6878-6903. doi: 10.3934/math.2024335
[2]	Turki D. Alharbi, Md Rifat Hasan . Global stability and sensitivity analysis of vector-host dengue mathematical model. AIMS Mathematics, 2024, 9(11): 32797-32818. doi: 10.3934/math.20241569
[3]	A. E. Matouk, Ismail Gad Ameen, Yasmeen Ahmed Gaber . Analyzing the dynamics of fractional spatio-temporal $\mathrm{SEIR}$ epidemic model. AIMS Mathematics, 2024, 9(11): 30838-30863. doi: 10.3934/math.20241489
[4]	Xinjie Zhu, Hua Liu, Xiaofen Lin, Qibin Zhang, Yumei Wei . Global stability and optimal vaccination control of SVIR models. AIMS Mathematics, 2024, 9(2): 3453-3482. doi: 10.3934/math.2024170
[5]	Rahman Ullah, Muhammad Farooq, Faiz Faizullah, Maryam A Alghafli, Nabil Mlaiki . Fractional stochastic functional differential equations with non-Lipschitz condition. AIMS Mathematics, 2025, 10(3): 7127-7143. doi: 10.3934/math.2025325
[6]	Muhammad Altaf Khan, Sajjad Ullah, Saif Ullah, Muhammad Farhan . Fractional order SEIR model with generalized incidence rate. AIMS Mathematics, 2020, 5(4): 2843-2857. doi: 10.3934/math.2020182
[7]	Yasir Nawaz, Muhammad Shoaib Arif, Wasfi Shatanawi, Muhammad Usman Ashraf . A new unconditionally stable implicit numerical scheme for fractional diffusive epidemic model. AIMS Mathematics, 2022, 7(8): 14299-14322. doi: 10.3934/math.2022788
[8]	Jutarat Kongson, Chatthai Thaiprayoon, Weerawat Sudsutad . Analysis of a mathematical model for the spreading of the monkeypox virus with constant proportional-Caputo derivative operator. AIMS Mathematics, 2025, 10(2): 4000-4039. doi: 10.3934/math.2025187
[9]	Minghung Lin, Yiyou Hou, Maryam A. Al-Towailb, Hassan Saberi-Nik . The global attractive sets and synchronization of a fractional-order complex dynamical system. AIMS Mathematics, 2023, 8(2): 3523-3541. doi: 10.3934/math.2023179
[10]	Mdi Begum Jeelani, Abeer S Alnahdi, Rahim Ud Din, Hussam Alrabaiah, Azeem Sultana . Mathematical model to investigate transmission dynamics of COVID-19 with vaccinated class. AIMS Mathematics, 2023, 8(12): 29932-29955. doi: 10.3934/math.20231531

Abstract

1. Introduction

Mathematics was initially utilized in biology in the $13^{th}$ century by Fibonacci, who developed the famed Fibonacci series to explain an increasing population. Daniel Bernoulli utilized mathematics to describe the impact on tiny shapes. Johannes Reinke coined the phrase "bio maths" in 1901. Biomathematics involves the theoretical examination of mathematical models to understand the principles governing the formation and functioning of biological systems.

Mathematical models are utilized to investigate specific questions related to the studied disease. For example, epidemiological models are important for predicting how infectious diseases spread, and help to control them by identifying important factors in the community. In this case, we want to analyze a particular model to understand how the COVID-19 virus behaves. This virus appeared in late 2019, and continues to be a global challenge. To gain a deeper insight into the underlying physical processes, we delve into the realm of fractional calculus. Previous literature has introduced various operators through the framework of fractional calculus ^[1,2]. In the field of C $^\eta$ -Calculus, Golmankhaneh et al. ^[3] provided an explanation of the Sumudu transform and Laplace transform. Additionally, in 2019, Goyal ^[4] proposed a fractional model that demonstrated the potential to manage the Lassa hemorrhagic fever disease.

Advancements in technology have led to significant progress in the field of epidemiology, enabling the examination of various infectious diseases for treatment, control, and cure ^[5]. It is essential to underscore that mathematical biology plays a pivotal role in investigating numerous diseases. Significant strides have been taken in the mathematical modeling of infectious diseases in recent decades, as evidenced by various studies ^[6,7]. Over the last thirty years, mathematical modeling has gained prominence in research, making substantial contributions to the development of effective public health strategies for disease control ^[8,9]. Mathematical models serve as invaluable tools for analyzing spatiotemporal patterns and the dynamic behavior of infections. Acknowledging their significance, researchers have approached the study of COVID-19 from diverse perspectives in the last three years ^[10,11].

Various methodologies have been employed by researchers in this field to devise successful techniques for managing this condition, with recent studies offering additional insights ^[12,13]. For example, a recent investigation utilized a mathematical model to evaluate the impacts of immunization in nursing homes ^[14]. Furthermore, researchers have explored mathematical modeling and effective intervention strategies for controlling the COVID-19 outbreak ^[15]. Additionally, some studies have delved into COVID-19 mathematical models using stochastic differential equations and environmental white noise ^[16].

In 2019, China experienced a notable outbreak of the coronavirus disease 2019 (COVID-19), prompting concerns about its potential to escalate into a worldwide pandemic ^[17]. Researchers from China, particularly Zhao et al., made significant contributions in addressing the challenges posed by COVID-19. This disease is attributed to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a viral infection. The initial verified case was documented in Wuhan, China, in December 2019 ^[18]. The infection rapidly spread worldwide, leading to the declaration of a COVID-19 pandemic.

Transmission occurs through various means, including respiratory droplets from coughing, sneezing, close contact, and touching contaminated surfaces. Key preventive measures include consistent mask usage, frequent hand washing, and maintaining safe interpersonal distances ^[19]. Effective interventions and real-time data play a crucial role in managing the coronavirus outbreak ^[20]. Prior studies have employed real-time analysis to comprehend the transmission of the virus among individuals, the severity of the disease, and the early stages of the pathogen, particularly in the initial week of the outbreak ^[21].

In December 2019, an outbreak of pneumonia cases was reported in Wuhan, initially with unidentified origins. Some cases were associated with exposure to wet markets and seafood. Chinese health authorities, in collaboration with the Chinese Center for Disease Control and Prevention (China CDC), initiated an investigation into the cause and spread of the disease on December 31, 2019 ^[22]. We conducted an analysis of temporal changes in the outbreak by examining the time interval between hospital admission dates and fatalities. Clinical studies on COVID-19 have indicated that symptoms typically manifest around 7 days after the onset of illness ^[23]. It is important to consider the duration between hospitalization and death in order to accurately assess the risk of mortality ^[24]. The information regarding the incubation period of COVID-19 and epidemiological data was sourced from publicly available records of confirmed cases ^[25].

An established method for the fractional-order model is elaborated upon in ^[26]. Recent contributions include various fractional models related to COVID-19, such as the analysis by Atangana and Khan focusing on the pandemic's impact on China ^[27]. Additionally, the COVID-19 model's dynamical aspects were explored using fuzzy Caputo and ABC derivatives, as demonstrated in ^[28]. A similar type of approach using fractional operator techniques are given in ^[29,30,31]. Different author's have investigated the transmission of different infectious disease like COVID-19 with symptomatic and asymptomatic effects in the community by using the fractal-fractional definition ^[32,33].

In light of the aforementioned significance, we aim is to address fundamental issues by concentrating on the distinctive challenges posed by the dynamics of COVID-19. To achieve this, we employ a model tailored to accurately capture the characteristics of COVID-19 dynamics and account for the limitations in our response to the pandemic. Initially, we examine the epidemic dynamics within a specific community characterized by a unique social pattern. For this analysis, we adopt a conventional SEIR design that accommodates prolonged incubation periods.

Here, the previous model is given in ^[34] as follows:

$\begin{eqnarray} \frac{dS}{dt}& = &\textbf{a}-\frac{\rho_{1} S I}{1+\gamma I}-(\delta+\rho)S,\\ \frac{dE}{dt}& = &\rho S-\delta E-\rho_{2}\alpha E I,\\ \frac{dI}{dt}& = &\frac{\rho_{1} S I}{1+\gamma I}\,\,+\rho_{2}\,\alpha\, E I-(\delta+\mu_{0}+\omega-\textbf{b})\,I,\\ \frac{dR}{dt}& = &\omega I-\delta R. \end{eqnarray}$

(1.1)

Initial conditions corresponds to the aforementioned system:

$\begin{equation*} S^{0}(t) \, = \, S_{0},\, \, E^{0}(t) \, = \, E_{0}, \, \,I^{0}(t) \, = \, I_{0},\,\, R^{0}(t)\, = \, R_{0}. \end{equation*}$

The primary goal of this research is to employ novel fractional derivatives within mathematical analysis and simulation to enhance the COVID-19 model. COVID-19 is a highly dangerous disease that presents a significant risk to human life. Verification of the existence and distinct characteristics of the solution system is undertaken, coupled with a qualitative assessment of the system. So, we introduce vaccination measures for low immune individuals. We developed new mathematical model by taking vaccination measures which helps to control COVID-19 early which we shall observe on simulation easily. The research involves confirming the presence of a solution system with unique characteristics and conducting a qualitative evaluation of this system. Furthermore, the fractal-fractional derivative is utilized to investigate the real-world behavior of the newly developed mathematical model. Finally, numerical simulations are used to reinforce and authenticate the biological findings.

Definition 1.1. If 0 $< \xi \leq$ 1 and 0 $< \lambda \leq$ 1, then the Riemann-Liouville operator for the fractal-fractional Operator (FFO) with a Mittag-Leffler (ML) kernel is defined as $U(t)$ ^[35].

$\begin{eqnarray} ^{FFM}_{0} D_{t}^{\xi, \lambda} U(t) = \frac{A B(\xi)}{1- \xi} \int^{t}_{0} E_{\xi} \frac{d \,U(\Omega)}{dt^{\lambda}}\left[- \frac{\xi}{1- \xi} (t-\Omega)^{\xi}\right] {d \Omega}\,\,, \end{eqnarray}$

involving $0 \; < \; \xi, \; \lambda \; \leq \; 1$ , and $AB(\xi) = 1 - \xi + \frac{\xi}{\Gamma(\xi)}.$

Therefore, the function $U(t)$ , which has an order of $(\xi, \lambda)$ and a Mittag-Leffler (ML) kernel, is given as follows:

$\begin{eqnarray} ^{FFM}_{0} D_{t}^{\xi, \lambda} U(t) = \frac{\lambda(1-\xi) t^{\lambda -1} U(t)}{A B(\xi)} + \frac{\xi \lambda}{A B(\xi)} \int^{t}_{0} {\Omega}^{\xi -1} (t-\Omega) U(\Omega) {d \Omega} \,\,. \end{eqnarray}$

2. Formulation of the SEVIR model

A newly developed model for SARS-COVID-19 includes the vaccinated effect, whereas the previous model used the SEIR framework. In this new model, we introduce a new variable called "Vaccinated." With the addition of Vaccinated, the new model is referred to as SEVIR, where "S" represents the Susceptible class, "E" represents the Exposed class, "V" represents the Vaccinated class, "I" represents the Infected class, and "R" represents the Recovered class.

We define several parameters in this model: "a" represents the recruitment rate, " $\delta$ " represents the death rate due to natural causes, " $\rho+\rho_{1}$ " represents the contact rate from the Susceptible class to the Exposed class, " $\rho_{2}$ " represents the vaccination rate, " $\alpha$ " represents the rate at which the infection is reducing due to vaccination effects, " $\mu_{0}$ " represents the infection death rate, " $\omega$ " represents the rate at which an individual recovers from vaccination and becomes recovered, " $\textbf{b}$ " represents the recruitment rate to the Vaccinated class, " $\phi$ " represents the contact rate from the Vaccinated class to the Infected class, and " $\psi$ " represents the recovery rate.

We want to investigate spread of the SEIR model for SARS-COVID-19 with the vaccinated effect.

So, the flow chart for newly developed model SEVIR is given as Figure 1.

Figure 1. The flow chart illustrates the newly developed model.

DownLoad: Full-Size Img PowerPoint

The model that was developed based on the generalized hypothesis with the vaccinated effect is presented as follows:

$\begin{eqnarray} \frac{d S}{dt}& = &\textbf{a}-(\delta+\rho+\rho_{1})S,\\ \frac{d E}{dt}& = &(\rho+\rho_{1})S-\delta E-\rho_{2}\alpha E V,\\ \frac{d V}{dt}& = &\rho_{2}\alpha E V-(\delta+\mu_{0}+\omega-\textbf{b}+\phi)V,\\ \frac{d I}{dt}& = &\phi V-(\mu_{0}+\delta+\psi)I,\\ \frac{d R}{dt}& = &\omega V+\psi I -\delta R. \end{eqnarray}$

(2.1)

The following are initial conditions linked with the described system:

$\begin{eqnarray} S^{0}(t) \, = \, S_{0},\, \, E^{0}(t) \, = \, E_{0}, \, \,V^{0}(t) \, = \, V_{0}, \, \,I^{0}(t) \, = \, I_{0},\,\, R^{0}(t)\, = \, R_{0}. \end{eqnarray}$

Using the fractal-fractional order (FFO) with a Mittag-Leffler (ML) definition, the above model becomes

$\begin{eqnarray} ^{FFM}_{0}D^{\xi,\lambda}_{t}S(t)& = &\textbf{a}-(\delta+\rho+\rho_{1})S,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t}E(t)& = &(\rho+\rho_{1})S-\delta E-\rho_{2}\alpha E V,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t}V(t)& = &\rho_{2}\alpha E V-(\delta+\mu_{0}+\omega-\textbf{b}+\phi)V,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t}I(t)& = &\phi V-(\mu_{0}+\delta+\psi)I,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t}R(t)& = &\omega V+\psi I-\delta R. \end{eqnarray}$

(2.2)

Here, $^{FFM}_{0}D^{\xi, \lambda}_{t}$ is the fractal-fractional operator with Mittag-Leffler (ML), where $0 < \xi \leq 1$ and $0 < \lambda \leq\; 1$ .

The following are initial conditions linked with the described system:

$\begin{eqnarray} S^{0}(t) \, = \, S_{0},\, \, E^{0}(t) \, = \, E_{0}, \, \,V^{0}(t) \, = \, V_{0}, \, \,I^{0}(t) \, = \, I_{0},\,\, R^{0}(t)\, = \, R_{0}. \end{eqnarray}$

Parameter descriptions are given in the following table.

Parameters	Representation	Reference
$\text{a}$	$\text{contact rate from the susceptible to the exposed class}$	^[34]
$\delta$	$\text{death rate due to natural causes}$	^[34]
$\rho+\rho_{1}$	$\text{contact rate from the susceptible to the exposed class}$	^[34]
$\alpha$	$\text{rate at which the infection is reducing due to vaccination}$	^[34]
$\rho_{2}$	$\text{vaccination rate}$	^[34]
$\mu_{0}$	death rate due to infection	^[34]
$\omega$	rate at which an individuals becomes recovered	^[34]
$\text{b}$	recruitment rate to the vaccinated class	^[34]
$\phi$	contact rate from the vaccinated to the infected class	Assumed
$\psi$	recovery rate	Assumed

2.1. Equilibrium point and reproductive number

For this model, the point of equilibrium without disease (disease free) is

$\begin{eqnarray} D_{1}(S,\,E,\,V,\,I,\,R) = \left(\frac{\textbf{a}}{\delta+\rho+\rho_{1}},\frac{\textbf{a}(\rho+\rho_{1})}{\delta(\delta+\rho+\rho_{1})},0,0,0\right), \end{eqnarray}$

as well as the endemic points of equilibrium $D_{2}(S^{*}, E^{*}, V^{*}, I^{*}, R^{*})$ , where

$\begin{eqnarray} S^{*}& = &\frac{\textbf{a}}{\delta+\rho+\rho_{1}},\\ E^{*}& = &\frac{-\textbf{b}+\delta+\phi+\omega+\mu_{0}}{\alpha\rho_{2}},\\ V^{*}& = &\frac{(\delta+\psi+\mu_{0})\textbf{A}-\textbf{b}\delta\rho_{1}+\delta^{2}\rho_{1}+\delta\phi\rho_{1}+\delta\omega\rho_{1}+\delta\mu_{0}\rho_{1}-\textbf{a}\alpha\rho\rho_{2}-\textbf{a}\alpha\rho_{1}\rho_{2}}{\alpha \phi(\textbf{b}-\delta-\phi-\omega-\mu_{0})(\delta+\rho+\rho_{1})\rho_{2}},\\ I^{*}& = &\phi\Bigg(\frac{\textbf{A}-\textbf{b}\delta\rho_{1}+\delta^{2}\rho_{1}+\delta\phi\rho_{1}+\delta\omega\rho_{1}+\delta\mu_{0}\rho_{1}-\textbf{a}\alpha\rho\rho_{2}-\textbf{a}\alpha\rho_{1}\rho_{2}}{\alpha(\textbf{b}-\delta-\phi-\omega-\mu_{0})(\delta+\rho+\rho_{1})\rho_{2}}\Bigg),\\ R^{*}& = &\big(\phi\psi+\delta\omega+\psi\omega+\omega\mu_{0}\big)\times\Bigg(\frac{\textbf{A}-\textbf{b}\delta\rho_{1}+\delta^{2}\rho_{1}+\delta\phi\rho_{1}+\delta\omega\rho_{1}+\delta\mu_{0}\rho_{1}-\textbf{a}\alpha\rho\rho_{2}-\textbf{a}\alpha\rho_{1}\rho_{2}}{\alpha \delta \phi(\delta+\psi+\mu_{0})(\textbf{b}-\delta-\phi-\omega-\mu_{0})(\delta+\rho+\rho_{1})\rho_{2}}\Bigg), \end{eqnarray}$

where

$\begin{eqnarray} \textbf{A} = -\textbf{b}\delta^{2}+\delta^{3}-\textbf{b}\delta\rho+\delta^{2}\rho+\delta^{2}\phi +\delta\rho\phi+\delta^{2}\omega+\delta\rho\omega+\delta^{2}\mu_{0}+\delta\rho\mu_{0}. \end{eqnarray}$

The reproductive number for the newly developed system by using the next generation method is

$\begin{eqnarray} R_{0} = \frac{\textbf{b}\delta(\delta+\rho+\rho_{1})+\textbf{a}\alpha\rho_{2}(\rho+\rho_{1})}{\delta(\delta+\rho+\rho_{1})(\delta+\phi+\omega+\mu_{0})}. \end{eqnarray}$

3. Bounded and positive solutions

In this section, we demonstrate the boundedness and positivity of the developed model.

Theorem 3.1. The considered initial condition is

$\begin{eqnarray} \{S_{0},E_{0}, V_{0},I_{0},R_{0}\}\subset\Upsilon, \end{eqnarray}$

and therefore the solutions $\{ S, E, V, I, R \}$ will be positive $\forall$ t $\geq$ 0.

Proof. We will begin the primary analysis to show the improved quality of the solutions. These solutions effectively address real-world issues and have positive outcomes. We will follow the methodology provided in references ^[36,37,38]. In this segment, we will examine the conditions required to ensure positive outcomes from the proposed model. To accomplish this, we will establish a standard.

$\begin{eqnarray} \parallel \beta \parallel_{\infty} = \sup\limits_{t\in D_{\beta}}\mid\beta(t)\mid, \end{eqnarray}$

where " $D_{\beta}$ " represents the $\beta$ domain. Now, we continue with $S(t)$ .

$\begin{eqnarray} ^{FFM}_{0}D^{\xi,\lambda}_{t}S(t)& = &\textbf{a}-(\delta+\rho+\rho_{1})S, \quad \forall t\geq0,\\ &\geq&-\left(\delta+\rho+\rho_{1}\right)S, \quad \forall t\geq0. \end{eqnarray}$

This yield

$\begin{eqnarray} S(t)\geq S(0)E_{\xi}\bigg[-\frac{c^{1-\lambda}{\xi}{(\delta+\rho+\rho_{1})}{t^{\xi}}}{{A B}(\xi)-(1-\xi)(\delta+\rho+\rho_{1})}\bigg], \quad \forall t\geq0, \end{eqnarray}$

where "c" represents the time element. This demonstrates that the $S(t)$ individuals must be positive $\forall \, \, t \geq$ 0. Now, we have the $E(t)$ individuals as follows:

$\begin{eqnarray} ^{FFM}_{0}D^{\xi,\lambda}_{t}E(t)& = &(\rho+\rho_{1})S-\delta E-\rho_{2}\alpha E V, \quad \forall \,\, t\geq0,\\ &\geq&-(\delta+\rho_{2}\alpha\mid V \mid)E, \quad \forall \,\,t\geq0,\\ &\geq&-(\delta+\rho_{2}\alpha\sup\limits_{t\in D_{V}}\mid V \mid )E, \quad \forall \,\,t\geq0,\\ &\geq&-(\delta+\rho_{2}\alpha\parallel V \parallel_{\infty})E, \quad \forall \,\,t\geq 0. \end{eqnarray}$

This yield

$\begin{eqnarray} E(t)\geq E(0)E_{\xi}\bigg[-\frac{c^{1-\lambda}{\xi}{(\delta+\rho_{2}\alpha\parallel V\parallel_{\infty})}{t^{\xi}}}{AB(\xi)-(1-\xi)(\delta+\rho_{2}\alpha\parallel V\parallel_{\infty})}\bigg], \quad \forall \,\,t\geq0, \end{eqnarray}$

where "c" represents the time element. This demonstrates that the $E(t)$ individuals must be positive $\forall \, \, t \geq$ 0. Now, we have the $V(t)$ individuals as follows:

$\begin{eqnarray} ^{FFM}_{0}D^{\xi,\lambda}_{t}V(t)& = &\rho_{2}\alpha E I-(\delta+\mu_{0}+\omega-\textbf{b}+\phi)V, \quad \forall t\geq0,\\ &\geq&-(-\rho_{2}\alpha \mid E \mid+\mu_{0}+\delta+\omega-\textbf{b}+\phi)V, \quad \forall t\geq0,\\ &\geq&-(-\rho_{2}\alpha \sup\limits_{t\in D_{E}}\mid E \mid+\mu_{0}+\delta+\omega-\textbf{b}+\phi)V, \quad \forall t\geq0,\\ &\geq&-(-\rho_{2}\alpha \parallel E \parallel_{\infty}+\mu_{0}+\delta+\omega-\textbf{b}+\phi)V, \quad \forall t\geq0. \end{eqnarray}$

This yield

$\begin{eqnarray} V(t)\geq V(0)E_{\xi}\bigg[-\frac{c^{1-\lambda{\xi}}{(-\rho_{2}\alpha \parallel E \parallel_{\infty}+\mu_{0}+\delta+\omega-\textbf{b}+\phi)}{t^{\xi}}}{A B(\xi)-(1-\xi)\left(-\rho_{2}\alpha\parallel E \parallel_{\infty}+\mu_{0}+\delta+\omega-\textbf{b}+\phi\right)}\bigg], \quad \forall t\geq0, \end{eqnarray}$

where "c" represents the time element. This demonstrates that the $V(t)$ individuals must be positive $\forall \, \, t \geq$ 0. Now, we have the $I(t)$ individuals as follows:

$\begin{eqnarray} ^{FFM}_{0}D^{\xi,\lambda}_{t}I(t)& = &\phi V-(\mu_{0}+\delta+\psi)I, \quad \forall t\geq0,\\ &\geq&-(\mu_{0}+\delta+\psi)I(t), \quad \forall t\geq0. \end{eqnarray}$

This yield

$\begin{eqnarray} I(t)\geq I(0)E_{\xi}\bigg[-\frac{c^{1-\lambda}{\xi}{(\mu_{0}+\delta+\psi)}{t^{\xi}}}{A B(\xi)-(1-\xi)(\mu_{0}+\delta+\psi)}\bigg], \quad \forall t\geq0, \end{eqnarray}$

where "c" represents the time element. This demonstrates that the $I(t)$ individuals must be positive $\forall \, \, t \geq$ 0. Now, we have the $R(t)$ individuals as follows:

$\begin{eqnarray} ^{FFM}_{0}D^{\xi,\lambda}_{t}R(t)& = &\omega V+\psi I-\delta R , \quad \forall \,t\,\geq\,0,\\ &\geq&-(\delta)R(t), \quad \forall \,t\,\geq\,0. \end{eqnarray}$

This yield

$\begin{eqnarray} R(t)\geq R(0){E_{\xi}}\bigg[-\frac{c^{1-\lambda}\xi{(\delta)}{t^{\xi}}}{{A B}(\xi)-(1-\xi)(\delta)}\bigg], \quad \forall t\geq0, \end{eqnarray}$

where "c" represents the time element. This demonstrates that the $R(t)$ individuals must be positive $\forall \, \, t \geq$ 0.

Theorem 3.2. Solutions of our developed model given in Eq (2.2) with positive initial values are all bounded.

Proof. The above theorem demonstrates that the solutions of our developed model must be positive $\forall \, \, t\, \geq\, 0$ , and the strategies are described in ^[39]. Because $X = S\, +\, E\, +\, V$ , then

$\begin{eqnarray} ^{FFM}_{0}D^{\xi,\lambda}_{t}X(t) = \textbf{a}-\delta X-(\mu_{0}+\omega-\textbf{b}+\phi)V. \end{eqnarray}$

We achieved as follows:

$\begin{eqnarray} \Psi_{p} = \{S,\quad E,\quad V \in R_{+}^{3}\mid S + V\leq X\} \quad \forall \,\,t\geq0. \end{eqnarray}$

Further we have $X_{\upsilon}$ = I+R. So, we have

$\begin{eqnarray} ^{FFM}_{0}D^{\xi,\lambda}_{t}X_{\upsilon}(t) = (\phi+\omega)V-\mu_{0}I-X_{\upsilon}\delta. \end{eqnarray}$

Upon solving the above equation and taking $t\rightarrow \infty$ , we get

$\begin{eqnarray} X_{\upsilon}\leq\frac{(\phi+\omega)V-\mu_{0}I}{\delta}. \end{eqnarray}$

Thus,

$\begin{eqnarray} \Psi_{\upsilon} = \bigg\{I,\,\,R\in R_{+}^{2}\mid X_{\upsilon}\leq\frac{(\phi+\omega)I-\mu_{0}Q}{\delta}\bigg\} \quad \forall \,\,t \geq 0. \end{eqnarray}$

The model's mathematical solutions (2.2) are confined to the region $\Psi$ .

$\begin{eqnarray} \Psi = \bigg\{S,\,\,E,\,\,V,\,\,I,\,\,R \in R_{+}^{5}\mid S+V\leq X,X_{\upsilon}\leq\frac{(\phi+\omega)V-\mu_{0}I}{\delta}\bigg\} \quad \forall \,\,t\geq0. \end{eqnarray}$

This demonstrates that for every $t \geq$ 0, all solutions remain positive, consistent with the provided initial conditions in the domain $\Psi$ .

Theorem 3.3. The proposed coronavirus model (2.2) in $R_{+}^{5}$ has positive invariant solutions, in addition to the initial conditions.

Proof. In this particular scenario, we applied the procedure described in ^[40]. We have

$\begin{eqnarray} ^{FFM}_{0}D^{\xi,\lambda}_{t}(S(t))_{S = 0}& = &\textbf{a} \quad \geq0,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t}(E(t))_{E = 0}& = &(\rho+\rho_{1})S \quad \geq0,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t}(V(t))_{V = 0}& = &\rho_{2}\alpha E V+\textbf{b}V \quad \geq0,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t}(I(t))_{I = 0}& = &\phi V \quad \geq0,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t}(R(t))_{R = 0}& = &\omega V+\psi I \quad \geq0. \end{eqnarray}$

(3.1)

If $(S_{0}, E_{0}, V_{0}, I_{0}, R_{0})$ $\in$ $R_{+}^{5}$ , then our obtained solution is unable to escape from the hyperplane, as stated in Eq (3.1). This proves that the $R_{+}^{5}$ domain is positive invariant.

4. Impact of global derivatives for uniqueness and existence of solutions

The Riemann-Stieltjes integral has been widely recognized in the literature as the most commonly used integral. If

$\begin{eqnarray} Y(x) = \int y(x){d}x, \end{eqnarray}$

then the Riemann-Stieltjes integral is given as follows:

$\begin{eqnarray} Y_{w}(x) = \int y(x){d}{w}(x), \end{eqnarray}$

where the $y(x)$ global derivative with respect to $w(x)$ is

$\begin{eqnarray} D_{w}y(x) = \lim\limits_{h\rightarrow0}\frac{y(x+h)-y(x)}{w(x+h)-w(x)}. \end{eqnarray}$

If the above function's numerator and denominator are differentiated, we get

$\begin{eqnarray} D_{w}y(x) = \frac{y^{'}(x)}{w^{'}(x)}, \end{eqnarray}$

assuming that $w^{'}(x)\, \, \neq$ 0, $\forall x\in D_{w^{'}}$ . Now, we will test the impact on the coronavirus by using the global derivative instead of the classical derivative:

$\begin{eqnarray} D_{w}S& = &\textbf{a}-(\delta+\rho+\rho_{1})S,\\ D_{w}E& = &(\rho+\rho_{1})S-\delta E-\rho_{2}\alpha E V,\\ D_{w}V& = &\rho_{2}\alpha E V-(\delta+\mu_{0}+\omega-\textbf{b}+\phi)V,\\ D_{w}I& = &\phi V-(\mu_{0}+\delta+\psi)I,\\ D_{w}R& = &\omega V+\psi I-\delta R. \end{eqnarray}$

For the sake of clean notation, we shall suppose that w is differentiable.

$\begin{eqnarray} S^{'}& = &w^{'}[\textbf{a}-(\delta+\rho+\rho_{1})S],\\ E^{'}& = &w^{'}[(\rho+\rho_{1})S-\delta E-\rho_{2}\alpha E V],\\ V^{'}& = &w^{'}[\rho_{2}\alpha E V-(\delta+\mu_{0}+\omega-\textbf{b}+\phi)V],\\ I^{'}& = &w^{'}[\phi V-(\mu_{0}+\delta+\psi)I],\\ R^{'}& = &w^{'}[\omega V+\psi I-\delta R]. \end{eqnarray}$

An appropriate choice of the function $w(t)$ will lead to a specific outcome. For instance, if $w(t) = t^{\alpha}$ , where $\alpha$ is a real number, we will observe fractal movement. We had to take action due to the circumstances that

$\begin{eqnarray} \parallel w^{'}\parallel_{\infty} = \sup\limits_{t\in D_{w^{'}}}\mid w^{'}(t)\mid < N. \end{eqnarray}$

The below example demonstrates the unique solution for the developed system:

$\begin{eqnarray} S^{'}& = &w^{'}[\textbf{a}-(\delta+\rho+\rho_{1})S] = Z_{1}(t, S, G),\\ E^{'}& = &w^{'}[(\rho+\rho_{1})S-\delta E-\rho_{2}\alpha E V] = Z_{2}(t, S, G),\\ V^{'}& = &w^{'}[\rho_{2}\alpha E V-(\delta+\mu_{0}+\omega- \textbf{b}+\phi)V] = Z_{3}(t, S, G), \\ I^{'}& = &w^{'}[\phi V-(\mu_{0}+\delta+\psi)I] = Z_{4}(t, S, G),\\ R^{'}& = &w^{'}[\omega V+\psi I-\delta R] = Z_{5}(t, S, G), \end{eqnarray}$

where $G = E, V, I, R$ .

We need to confirm the first two requirements as follows:

(1) $\mid Z(t, S, G)\mid^{2} < K(1+\mid S\mid^{2}$ ,

(2) $\forall \quad S_{1}, S_{2}$ , we have, $\parallel Z(t, S_{1}, G)-Z(t, S_{2}, G)\parallel^{2} < \bar{K}\parallel S_{1}-S_{2}\parallel_{\infty}^{2}$ .

Initially,

$\begin{eqnarray} \mid Z_{1}(t, S, G)\mid^{2}& = &\mid w^{'}\big[\textbf{a}-(\delta+\rho+\rho_{1})S\big]\mid^{2},\\ & = &\mid w^{'}\big[\textbf{a}+\left(-\delta-\rho-\rho_{1}\right)S\big]\mid^{2},\\ &\leq&2\mid w^{'}\mid^{2}\left(\textbf{a}^{2}+\mid(-\delta-\rho-\rho_{1})S\mid^{2}\right),\\ &\leq&2\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}\textbf{a}^{2}+6\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}\left(\rho^{2}+\delta^{2}+\rho_{1}\right)\mid S\mid^{2},\\ &\leq&2\parallel w^{'}\parallel^{2}_{\infty}\textbf{a}^{2}+6\parallel w^{'}\parallel^{2}_{\infty}\left(\rho^{2}+\delta^{2}+\rho_{1}^{2}\right)\mid S\mid^{2},\\ &\leq&2\parallel w^{'}\parallel^{2}_{\infty}\textbf{a}^{2}\left(1+\frac{3}{\textbf{a}^{2}}(\rho^{2}+\delta^{2}+\rho_{1}^{2})\mid S\mid^{2}\right),\\ &\leq&K_{1}(1+\mid S\mid^{2}), \end{eqnarray}$

under the condition

$\begin{eqnarray} \frac{3}{\textbf{a}^{2}}(\rho^{2}+\delta^{2}+\rho_{1}^{2}) < 1, \end{eqnarray}$

involving

$\begin{eqnarray} K_{1} = 2\parallel w^{'}\parallel^{2}_{\infty}\textbf{a}^{2}. \end{eqnarray}$

$\begin{eqnarray} \mid Z_{2}(t, S, G)\mid^{2}& = &\mid w^{'}\big[(\rho+\rho_{1})S-\delta E-\rho_{2}\alpha E V\big]\mid^{2},\\ & = &\mid w^{'}\big[(\rho+\rho_{1})S+(-\delta-\rho_{2}\alpha V)E\big]\mid^{2},\\ &\leq&2\mid w^{'}\mid^{2}\left(\mid(\rho+\rho_{1})S\mid^{2}+(-\delta-\rho_{2}\alpha V)E\mid^{2}\right),\\ &\leq&4\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}(\rho^{2}+\rho_{1}^{2})\sup\limits_{t\in D_{S}}\mid S\mid^{2}+4\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}(\delta^{2}+\rho^{2}_{2}\alpha^{2}\sup\limits_{t\in D_{V}}\mid V \mid^{2})\mid E\mid^{2},\\ &\leq&4\parallel w^{'}\parallel^{2}_{\infty}(\rho^{2}+\rho_{1}^{2})\parallel S\parallel^{2}_{\infty}+4\parallel w^{'}\parallel^{2}_{\infty}(\delta^{2}+\rho^{2}_{2}\alpha^{2}\parallel V \parallel^{2}_{\infty})\mid E\mid^{2},\\ &\leq&4\parallel w^{'}\parallel^{2}_{\infty}(\rho^{2}+\rho_{1}^{2})\parallel S\parallel^{2}_{\infty}\left(1+\frac{(\delta^{2}+\rho^{2}_{2}\alpha^{2}\parallel V \parallel^{2}_{\infty})\mid E\mid^{2}}{(\rho^{2}+\rho_{1}^{2})\parallel S\parallel^{2}_{\infty}}\right),\\ &\leq&K_{2}(1+\mid E\mid^{2}), \end{eqnarray}$

under the condition

$\begin{eqnarray} \frac{(\delta^{2}+\rho^{2}_{2}\alpha^{2}\parallel V \parallel^{2}_{\infty})}{(\rho^{2}+\rho_{1}^{2})\parallel S\parallel^{2}_{\infty}} < 1, \end{eqnarray}$

where

$\begin{eqnarray} K_{2} = 2\parallel w^{'}\parallel^{2}_{\infty}(\rho^{2}+\rho_{1}^{2})\parallel S\parallel^{2}_{\infty}. \end{eqnarray}$

$\begin{eqnarray} \mid Z_{3}(t, S, G)\mid^{2}& = &\mid w^{'}\big[\rho_{2}\alpha E V-(\delta+\mu_{0}+\omega-\textbf{b}+\phi)V\big]\mid^{2},\\ & = &\mid w^{'}\big[\rho_{2}\alpha E V+\textbf{b}V+(-\delta-\mu_{0}-\omega-\phi)V\big]\mid^{2},\\ &\leq&2\mid w^{'}\mid^{2}\left(\mid\rho_{2}\alpha E+\textbf{b}\mid^{2}+\mid(-\delta-\mu_{0}-\omega-\phi)\mid^{2}\right)\mid V \mid^{2},\\ &\leq&4\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}\big[(\rho_{2}^{2}\alpha^{2}\sup\limits_{t\in D_{E}}\mid E\mid^{2}+\textbf{b}^{2})+2(\delta^{2}+\mu_{0}^{2}+\omega^{2}+\phi^{2})\big]\mid V \mid^{2},\\ &\leq&4\parallel\mid w^{'}\parallel^{2}_{\infty}\bigg[(\rho_{2}^{2}\alpha^{2}\parallel E\parallel^{2}_{\infty}+\textbf{b}^{2})+2(\delta^{2}+\mu_{0}^{2}+\omega^{2}+\phi^{2})\bigg]\mid V \mid^{2},\\ &\leq&4\parallel\mid w^{'}\parallel^{2}_{\infty}(\rho_{2}^{2}\alpha^{2}\parallel E\parallel^{2}_{\infty}+\textbf{b}^{2})\bigg[1+\frac{2(\delta^{2}+\mu_{0}^{2}+\omega^{2}+\phi^{2})}{\left(\rho_{2}^{2}\alpha^{2}\parallel E\parallel^{2}_{\infty}+\textbf{b}^{2}\right)}\bigg]\mid V \mid^{2},\\ &\leq&K_{3}(2\mid V \mid^{2}), \end{eqnarray}$

under the condition

$\begin{eqnarray} \frac{2(\delta^{2}+\mu_{0}^{2}+\omega^{2}+\phi^{2})}{\left(\rho_{2}^{2}\alpha^{2}\parallel E\parallel^{2}_{\infty}+\textbf{b}^{2}\right)}\leq1, \end{eqnarray}$

where

$\begin{eqnarray} K_{3} = 4\parallel\mid w^{'}\parallel^{2}_{\infty}(\rho_{2}^{2}\alpha^{2}\parallel E\parallel^{2}_{\infty}+\textbf{b}^{2}). \end{eqnarray}$

$\begin{eqnarray} \mid Z_{4}(t, S, G)\mid^{2}& = &\mid w^{'}\big[\phi V-(\mu_{0}+\delta+\psi)I\big]\mid^{2},\\ & = &\mid w^{'}\big[\phi V+(-\mu_{0}-\delta-\psi)I\big]\mid^{2},\\ &\leq&2\mid w^{'}\mid^{2}\left(\mid\phi V \mid^{2}+\mid(-\mu_{0}-\delta-\psi)I\mid^{2}\right),\\ &\leq&2\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}\phi^{2}\sup\limits_{t\in D_{V}}\mid V \mid^{2}+6\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}(\mu_{0}^{2}+\delta^{2}+\psi^{2})\mid I \mid^{2},\\ &\leq&2\parallel w^{'}\parallel^{2}_{\infty}\phi^{2}\parallel V \parallel^{2}_{\infty}+6\parallel w^{'}\parallel^{2}_{\infty}(\mu_{0}^{2}+\delta^{2}+\psi^{2})\mid I\mid^{2},\\ &\leq&2\parallel w^{'}\parallel^{2}_{\infty}\phi^{2}\parallel I\parallel^{2}_{\infty}\left(1+\frac{3(\mu_{0}^{2}+\delta^{2}+\psi^{2})\mid I \mid^{2}}{\phi^{2}\parallel I\parallel^{2}_{\infty}}\right),\\ &\leq&K_{4}(1+\mid I \mid^{2}), \end{eqnarray}$

under the condition

$\begin{eqnarray} \frac{3(\mu_{0}^{2}+\delta^{2}+\psi^{2})}{\phi^{2}\parallel V \parallel^{2}_{\infty}} < 1, \end{eqnarray}$

where

$\begin{eqnarray} K_{4} = 2\parallel w^{'}\parallel^{2}_{\infty}\phi^{2}\parallel V \parallel^{2}_{\infty}. \end{eqnarray}$

$\begin{eqnarray} \mid Z_{5}(t, S, G)\mid^{2}& = &\mid w^{'}\big[\omega V+\psi I-\delta R\big]\mid^{2},\\ & = &\mid w^{'}\big[(\omega V+\psi I)+(-\delta R)\big]\mid^{2},\\ &\leq&2\mid w^{'}\mid^{2}\left(\mid(\omega V+\psi I)\mid^{2}+\mid-\delta R\mid^{2}\right),\\ &\leq&4\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}\left(\omega^{2}\sup\limits_{t\in D_{V}}\mid V \mid^{2}+\psi\sup\limits_{t\in D_{I}}\mid I \mid^{2}\right)+2\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}\delta^{2}\mid R\mid^{2},\\ &\leq&4\parallel w^{'}\parallel^{2}_{\infty}\left(\omega^{2}\parallel V \parallel^{2}_{\infty}+\psi\parallel I \parallel^{2}_{\infty}\right)+2\parallel w^{'}\parallel^{2}_{\infty}\delta^{2}\mid R\mid^{2}),\\ &\leq&4\parallel w^{'}\parallel^{2}_{\infty}(\omega^{2}\parallel V \parallel^{2}_{\infty}+\psi^{2}\parallel I\parallel^{2}_{\infty})\left(1+\frac{\delta^{2}\mid R\mid^{2}}{2(\omega^{2}\parallel V \parallel^{2}_{\infty}+\psi^{2}\parallel I \parallel^{2}_{\infty})}\right),\\ &\leq&K_{5}(1+\mid R\mid^{2}), \end{eqnarray}$

under the condition

$\begin{eqnarray} \frac{\delta^{2}}{2(\omega^{2}\parallel V \parallel^{2}_{\infty}+\psi^{2}\parallel I \parallel^{2}_{\infty})} < 1, \end{eqnarray}$

where

$\begin{eqnarray} K_{5} = 4\parallel w^{'}\parallel^{2}_{\infty}(\omega^{2}\parallel V \parallel^{2}_{\infty}+\psi^{2}\parallel I \parallel^{2}_{\infty}). \end{eqnarray}$

Hence the linear growth condition is satisfied.

Further, we validate the Lipschitz condition.

$\begin{eqnarray} \mid Z_{1}(t, S_{1}, G)-Z_{1}(t, S_{2}, G)\mid^{2}& = &\mid w^{'}(-\delta-\rho-\rho_{1})(S_{1}-S_{2})\mid^{2},\\ \mid Z_{1}(t, S_{1}, G)-Z_{1}(t, S_{2}, G)\mid^{2}&\leq&\mid w^{'}\mid^{2}(3\delta^{2}+3\rho^{2}+3\rho_{1}^{2})\mid S_{1}-S_{2}\mid^{2},\\ \sup\limits_{t\in D_{S}}\mid Z_{1}(t, S_{1}, G)-Z_{1}(t, S_{2}, G)\mid^{2}&\leq&\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}\left(3\delta^{2}+3\rho^{2}+3\rho_{1}^{2}\right)\sup\limits_{t\in D_{S}}\mid S_{1}-S_{2}\mid^{2},\\ \parallel Z_{1}(t, S_{1}, G)-Z_{1}(t, S_{2}, G)\parallel_{\infty}^{2}&\leq&\parallel w^{'}\parallel^{2}_{\infty}(3\delta^{2}+3\rho^{2}+3\rho_{1}^{2})\parallel S_{1}-S_{2}\parallel^{2}_{\infty},\\ \parallel Z_{1}(t, S_{1}, G)-Z_{1}(t, S_{2}, G)\parallel_{\infty}^{2}&\leq&\bar{K_{1}}\parallel S_{1}-S_{2}\parallel^{2}_{\infty}, \end{eqnarray}$

where

$\begin{eqnarray} \bar{K_{1}} = \parallel w^{'}\parallel^{2}_{\infty}\left(3\delta^{2}+3\rho^{2}+3\rho_{1}^{2}\right). \end{eqnarray}$

$\begin{eqnarray} \mid Z_{2}(t,\,\,S,\,\,E_{1},\,\,V,\,\,I,\,\,R)-Z_{2}(t,\,\,S,\,\,E_{2},\,\,V,\,\,I,\,\,R)\mid^{2}& = &\mid w^{'}(-\delta-\rho_{2}\alpha V)(E_{1}-E_{2})\mid^{2},\\ \mid Z_{2}(t,\,\,S,\,\,E_{1},\,\,V,\,\,I,\,\,R)-Z_{2}(t,\,\,S,\,\,E_{2},\,\,V,\,\,I,\,\,R)\mid^{2}&\leq&\mid w^{'}\mid^{2}(2\delta^{2}+2\rho_{2}^{2}\alpha^{2}\mid V \mid^{2})\mid E_{1}-E_{2}\mid^{2},\\ \sup\limits_{t\in D_{E}}\mid Z_{2}(t,\,\,S,\,\,E_{1},\,\,V,\,\,I,\,\,R)-Z_{2}(t,\,\,S,\,\,E_{2},\,\,V,\,\,I,\,\,R)\mid^{2}&\leq&\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}(2\delta^{2}+2\rho_{2}^{2}\alpha^{2}\sup\limits_{t\in D_{V}}\mid V \mid^{2})\sup\limits_{t\in D_{E}}\\&&\times\mid E_{1}-E_{2}\mid^{2},\\ \parallel Z_{2}(t,\,\,S,\,\,E_{1},\,\,V,\,\,I,\,\,R)-Z_{2}(t,\,\,S,\,\,E_{2},\,\,V,\,\,I,\,\,R)\parallel_{\infty}^{2}&\leq&\parallel w^{'}\parallel^{2}_{\infty}(2\delta^{2}+2\rho_{2}^{2}\alpha^{2}\parallel V \parallel^{2}_{\infty}),\parallel E_{1}-E_{2}\parallel^{2}_{\infty},\\ \parallel Z_{2}(t,\,\,S,\,\,E_{1},\,\,V,\,\,I,\,\,R)-Z_{2}(t,\,\,S,\,\,E_{2},\,\,V,\,\,I,\,\,R)\parallel_{\infty}^{2}&\leq&\bar{K_{2}}\parallel E_{1}-E_{2}\parallel^{2}_{\infty}, \end{eqnarray}$

where

$\begin{eqnarray} \bar{K_{2}} = \parallel w^{'}\parallel^{2}_{\infty}(2\delta^{2}+2\rho_{2}^{2}\alpha^{2}\parallel V \parallel^{2}_{\infty}). \end{eqnarray}$

$\begin{eqnarray} &&\mid Z_{3}(t,\,\,S,\,\,E,\,\,V_{1},\,\,I,\,\,R)-Z_{3}(t,\,\,S,\,\,E,\,\,V_{2},\,\,I,\,\,R)\mid^{2}\\& = &\mid w^{'}\left(\rho_{2}\alpha E+\textbf{b}+(-\delta-\mu_{0}-\omega-\phi)\right)(V_{1}-V_{2})\mid^{2}, \end{eqnarray}$

$\begin{eqnarray} &&\mid Z_{3}(t,\,\,S,\,\,E,\,\,V_{1},\,\,I,\,\,R)-Z_{3}(t,\,\,S,\,\,E,\,\,V_{2},\,\,I,\,\,R)\mid^{2}\\&\leq&2\mid w^{'}\mid^{2}\left(\mid\rho_{2}\alpha E+\textbf{b}\mid^{2}+\mid(-\delta-\mu_{0}-\omega-\phi)\mid^{2}\right)\\&&\times\mid V_{1}-V_{2}\mid^{2}, \end{eqnarray}$

$\begin{eqnarray} \sup\limits_{t\in D_{V}}\mid Z_{3}(t,\,\,S,\,\,E,\,\,V_{1},\,\,I,\,\,R)-Z_{3}(t,\,\,S,\,\,E,\,\,V_{2},\,\,I,\,\,R)\mid^{2}&\leq&4\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}\bigg(\rho_{2}^{2}\alpha^{2}\sup\limits_{t\in D_{E}}\mid E\mid^{2}+\textbf{b}^{2}\\&&+2(\delta^{2}+\mu_{0}^{2}+\omega^{2}+\phi^{2})\bigg)\sup\limits_{t\in D_{V}}\mid V_{1}-V_{2}\mid^{2},\\ \parallel Z_{3}(t,\,\,S,\,\,E,\,\,V_{1},\,\,I,\,\,R)-Z_{3}(t,\,\,S,\,\,E,\,\,V_{2},\,\,I,\,\,R)\parallel_{\infty}^{2}&\leq&4\parallel w^{'}\parallel^{2}_{\infty}\bigg(\rho_{2}^{2}\alpha^{2}\parallel E\parallel^{2}_{\infty}+\textbf{b}^{2}\\&&+2(\delta^{2}+\mu_{0}^{2}+\omega^{2}+\phi^{2})\bigg)\parallel V_{1}-V_{2}\parallel^{2}_{\infty},\\ \parallel Z_{3}(t,\,\,S,\,\,E,\,\,V_{1},\,\,I,\,\,R)-Z_{3}(t,\,\,S,\,\,E,\,\,V_{2},\,\,I,\,\,R)\parallel_{\infty}^{2}&\leq&\bar{K_{3}}\parallel V_{1}-V_{2}\parallel^{2}_{\infty}, \end{eqnarray}$

where

$\begin{eqnarray} \bar{K_{3}} = 4\parallel w^{'}\parallel^{2}_{\infty}\bigg(\rho_{2}^{2}\alpha^{2}\parallel E\parallel^{2}_{\infty}+\textbf{b}^{2}+2(\delta^{2}+\mu_{0}^{2}+\omega^{2}+\phi^{2})\bigg). \end{eqnarray}$

$\begin{eqnarray} \mid Z_{4}(t,\,\,S,\,\,E,\,\,V,\,\,I_{1},\,\,R)-Z_{4}(t,\,\,S,\,\,E,\,\,V,\,\,I_{2},\,\,R)\mid^{2}& = &\mid w^{'}(-\mu_{0}-\delta-\psi)\big](Q_{1}-Q_{2})\mid^{2},\\ \mid Z_{4}(t,\,\,S,\,\,E,\,\,V,\,\,I_{1},\,\,R)-Z_{4}(t,\,\,S,\,\,E,\,\,V,\,\,I_{2},\,\,R)\mid^{2}& = &\mid w^{'}\mid^{2}(3\mu_{0}^{2}+3\delta^{2}+3\psi^{2})\mid I_{1}-I_{2}\mid^{2},\\ \sup\limits_{t\in D_{I}}Z_{4}(t,\,\,S,\,\,E,\,\,V,\,\,I_{1},\,\,R)-Z_{4}(t,\,\,S,\,\,E,\,\,V,\,\,I_{2},\,\,R)\mid^{2}& = &\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}(3\mu_{0}^{2}+3\delta^{2}+3\psi^{2})\sup\limits_{t\in D_{I}}\mid I_{1}-I_{2}\mid^{2},\\ \parallel Z_{4}(t,\,\,S,\,\,E,\,\,V,\,\,I_{1},\,\,R)-Z_{4}(t,\,\,S,\,\,E,\,\,V,\,\,I_{2},\,\,R)\parallel_{\infty}^{2}&\leq&\parallel w^{'}\parallel^{2}_{\infty}(3\mu_{0}^{2}+3\delta^{2}+3\psi^{2})\parallel I_{1}-I_{2}\parallel^{2}_{\infty},\\ \parallel Z_{4}(t,\,\,S,\,\,E,\,\,V,\,\,I_{1},\,\,R)-Z_{4}(t,\,\,S,\,\,E,\,\,V,\,\,I_{2},\,\,R)\parallel_{\infty}^{2}&\leq&\bar{K_{4}}\parallel I_{1}-I_{2}\parallel^{2}_{\infty}, \end{eqnarray}$

where

$\begin{eqnarray} \bar{K_{4}} = \parallel w^{'}\parallel^{2}_{\infty}(3\mu_{0}^{2}+3\delta^{2}+3\psi^{2}). \end{eqnarray}$

$\begin{eqnarray} \mid Z_{5}(t,\,\,S,\,\,E,\,\,V,\,\,I,\,\,R_{1})-Z_{5}(t,\,\,S,\,\,E,\,\,V,\,\,I,\,\,R_{2})\mid^{2}& = &\mid w^{'}(-\delta)(R_{1}-R_{2})\mid^{2},\\ \mid Z_{5}(t,\,\,S,\,\,E,\,\,V,\,\,I,\,\,R_{1})-Z_{5}(t,\,\,S,\,\,E,\,\,V,\,\,I,\,\,R_{2})\mid^{2}&\leq&\mid w^{'}\mid^{2}\delta^{2}\mid(R_{1}-R_{2})\mid^{2},\\ \sup\limits_{t\in D_{R}}\mid Z_{5}(t,\,\,S,\,\,E,\,\,V,\,\,I,\,\,R_{1})-Z_{5}(t,\,\,S,\,\,E,\,\,V,\,\,I,\,\,R_{2})\mid^{2}&\leq&\sup\limits_{t\in D_{w^{'}}}\mid w^{'}\mid^{2}\delta^{2}\sup\limits_{t\in D_{R}}\mid R_{1}-R_{2}\mid^{2},\\ \parallel Z_{5}(t,\,\,S,\,\,E,\,\,V,\,\,I,\,\,R_{1})-Z_{5}(t,\,\,S,\,\,E,\,\,V,\,\,I,\,\,R_{2})\parallel_{\infty}^{2}&\leq&\parallel w^{'}\parallel^{2}_{\infty}\delta^{2}\parallel R_{1}-R_{2}\parallel_{\infty}^{2},\\ \parallel Z_{5}(t,\,\,S,\,\,E,\,\,V,\,\,I,\,\,R_{1})-Z_{5}(t,\,\,S,\,\,E,\,\,V,\,\,I,\,\,R_{2})\parallel_{\infty}^{2}&\leq&\bar{K_{5}}\parallel R_{1}-R_{2}\parallel^{2}_{\infty}, \end{eqnarray}$

involving

$\begin{eqnarray} \bar{K_{5}} = \parallel w^{'}\parallel^{2}_{\infty}\delta^{2}. \end{eqnarray}$

Then, given the condition, system (2.2) has a particular solution.

$\begin{eqnarray} \max\Big[\frac{3}{\textbf{a}^{2}}(\rho^{2}+\delta^{2}+\rho_{1}^{2}),\frac{(\delta^{2}+\rho^{2}_{2}\alpha^{2}\parallel V \parallel^{2}_{\infty})}{(\rho^{2}+\rho_{1}^{2})\parallel S\parallel^{2}_{\infty}},\frac{2(\delta^{2}+\mu_{0}^{2}+\omega^{2}+\phi^{2})}{\left(\rho_{2}^{2}\alpha^{2}\parallel E\parallel^{2}_{\infty}+\textbf{b}^{2}\right)},\frac{3(\mu_{0}^{2}+\delta^{2}+\psi^{2})}{\phi^{2}\parallel V \parallel^{2}_{\infty}},\\ \frac{\delta^{2}}{2(\omega^{2}\parallel V \parallel^{2}_{\infty}+\psi^{2}\parallel I \parallel^{2}_{\infty})}\Big] < 1. \end{eqnarray}$

5. Global stability for developed system

We use Lyapunov's approach and LaSalle's concept of invariance to analyze global stability and determine the conditions for eliminating diseases.

5.1. Lyapunov's first derivative

Theorem 5.1. ^[41] When the reproductive number $R_{0} >$ 1, the endemic equilibrium points of the SEVIR model are globally asymptotically stable.

Proof. The Lyapunov function can be expressed in the following manner:

$\begin{eqnarray} L(S^{*},E^{*},V^{*},I^{*},R^{*})& = &\left(S-S^{*}-S^{*}\log\frac{S}{S^{*}}\right)+\left(E-E^{*}-E^{*}\log\frac{E}{E^{*}}\right) +\left(V-V^{*}-V^{*}\log\frac{V}{V^{*}}\right)\\ &&+\left(I-I^{*}-I^{*}\log\frac{I}{I^{*}}\right)+\left(R-R^{*}-R^{*}\log\frac{R}{R^{*}}\right). \end{eqnarray}$

By applying a derivative on both sides,

$\begin{eqnarray} D^{\xi,\lambda}_{t} L = \dot{L} = \left(\frac{S-S^{*}}{S}\right)D^{\xi,\lambda}_{t}S+\left(\frac{E-E^{*}}{E}\right)D^{\xi,\lambda}_{t}E+\left(\frac{V-V^{*}}{V}\right)D^{\xi,\lambda}_{t}V+\left(\frac{I-I^{*}}{I}\right)D^{\xi,\lambda}_{t}I+\left(\frac{R-R^{*}}{R}\right)D^{\xi,\lambda}_{t}R, \end{eqnarray}$

we get

$\begin{eqnarray} D^{\xi,\lambda}_{t} L & = &\left(\frac{S-S^{*}}{S}\right)\left(\textbf{a}-(\delta+\rho+\rho_{1})S\right) +\left(\frac{E-E^{*}}{E}\right)\left((\rho+\rho_{1})S-\delta E-\rho_{2}\alpha E V\right)+\left(\frac{V-V^{*}}{V}\right)\\&&\times\left(\rho_{2}\alpha E V -(\delta+\mu_{0}+\omega-\textbf{b}+\phi)V\right)+\left(\frac{I-I^{*}}{I}\right)\left(\phi V-(\mu_{0}+\delta+\psi)I\right)+\left(\frac{R-R^{*}}{R}\right)\\&&\times\left(\omega V+\psi I-\delta R\right), \end{eqnarray}$

and setting $S = S-S^{*}, E = E-E^{*}, V = V-V^{*}, I = I-I^{*}$ and $R = R-R^{*}$ results in

$\begin{eqnarray} D^{\xi,\lambda}_{t} L& = &\textbf{a}-\textbf{a}\frac{S^{*}}{S}-(\delta+\rho+\rho_{1})\frac{(S-S^{*})^{2}}{S} +(\rho+\rho_{1})S-(\rho+\rho_{1})S^{*}-(\rho+\rho_{1})S\frac{E^{*}}{E}+(\rho+\rho_{1})S^{*}\frac{E^{*}}{E} \\&&-\delta\frac{(E-E^{*})^{2}}{E}-\rho_{2}\alpha V\frac{(E-E^{*})^{2}}{E}+\rho_{2}\alpha V^{*}\frac{(E-E^{*})^{2}}{E}+\rho_{2}\alpha E\frac{(V-V^{*})^{2}}{V}-\rho_{2}\alpha E^{*}\frac{(V-V^{*})^{2}}{V} \\&&+\textbf{b}\frac{(V-V^{*})^{2}}{V}-(\delta+\mu_{0}+\omega+\phi)\frac{(V-V^{*})^{2}}{V}+\phi V-\phi V^{*}-\phi V\frac{I^{*}}{I}+\phi V^{*}\frac{I^{*}}{I}\\&&-(\mu_{0}+\delta+\psi)\frac{(I-I^{*})^{2}}{I}+\omega V -\omega V^{*}-\omega V\frac{R^{*}}{R}+\omega V^{*}\frac{R^{*}}{R}+\psi I-\psi I^{*}\\&&-\psi I\frac{R^{*}}{R}+\psi I^{*}\frac{R^{*}}{R}-\delta\frac{(R-R^{*})^{2}}{R}. \end{eqnarray}$

We can write $D^{\xi, \lambda}_{t} L = \Sigma-\Omega$ , where

$\begin{eqnarray} \Sigma& = &\textbf{a}+(\rho+\rho_{1})S+(\rho+\rho_{1})S^{*}\frac{E^{*}}{E}+\rho_{2}\alpha V^{*}\frac{(E-E^{*})^{2}}{E}+\rho_{2}\alpha E\frac{(V-V^{*})^{2}}{V}+\textbf{b}\frac{(V-V^{*})^{2}}{V} +\phi V\\&&+\phi V^{*}\frac{I^{*}}{I}+\omega V+\omega V^{*}\frac{R^{*}}{R}+\psi I+\psi I^{*}\frac{R^{*}}{R}, \end{eqnarray}$

and

$\begin{eqnarray} \Omega& = &\textbf{a}\frac{S^{*}}{S}+(\delta+\rho+\rho_{1})\frac{(S-S^{*})^{2}}{S}+(\rho+\rho_{1})S^{*} +(\rho+\rho_{1})S\frac{E^{*}}{E}+\delta\frac{(E-E^{*})^{2}}{E}+\rho_{2}\alpha V\frac{(E-E^{*})^{2}}{E}\\&&+\rho_{2}\alpha E^{*}\frac{(V-V^{*})^{2}}{V}+(\delta+\mu_{0}+\omega+\phi)\frac{(V-V^{*})^{2}}{V}+\phi V^{*}+\phi V\frac{I^{*}}{I}+(\mu_{0}+\delta+\psi)\frac{(I-I^{*})^{2}}{I} +\omega V^{*}\\&&+\omega V\frac{R^{*}}{R}+\psi V^{*}+\psi I\frac{R^{*}}{R}+\delta\frac{(R-R^{*})^{2}}{R}. \end{eqnarray}$

We conclude that if $\Sigma < \Omega$ , this yields $D^{\xi, \lambda}_{t} L < 0$ , however when $S = S^{*}, E = E^{*}, V = V^{*}, I = I^{*}$ and $R = R^{*}$ , $\Sigma-\Omega = 0 \quad \Rightarrow D^{\xi, \lambda}_{t} L = 0$ .

We can observe that $\left\{(S^{*}, E^{*}, V^{*}, I^{*}, R^{*})\in\Gamma : D^{\xi, \lambda}_{t} L = 0\right\}$ represents the point $D_2$ for the developed model.

According to Lasalles' concept of invariance, $D_2$ is globally uniformly stable in $\Gamma$ if $\Sigma-\Omega = 0$ .

6. Solutions by fractal-fractional operator

Now, we will develop a solution using a numerical approach for our newly developed model given in Eq (2.2). We use the ML kernel in the current scenario instead of the classical derivative operator.

Furthermore, we will use the variable order version.

$\begin{eqnarray} ^{FFM}_{0}D^{\xi,\lambda}_{t} S(t)& = &\textbf{a}-(\delta+\rho+\rho_{1})S,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t} E(t)& = &(\rho+\rho_{1})S-\delta E-\rho_{2}\alpha E V,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t} V(t)& = &\rho_{2}\alpha E V-(\delta+\mu_{0}+\omega-\textbf{b}+\phi)V,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t} I(t)& = &\phi V-(\mu_{0}+\delta+\psi)I,\\ ^{FFM}_{0}D^{\xi,\lambda}_{t} R(t)& = &\omega V+\psi I-\delta R. \end{eqnarray}$

For clarity, we express the above equation as follows:

$\begin{eqnarray} ^{FFM}_{0}D^{\xi,\lambda}_{t} S(t)& = &S_{1}(t, S, G),\\ ^{FFM}_{0}D^{\xi,\lambda}_{t} E(t)& = &E_{1}(t, S, G),\\ ^{FFM}_{0}D^{\xi,\lambda}_{t} V(t)& = &V_{1}(t, S, G),\\ ^{FFM}_{0}D^{\xi,\lambda}_{t} I(t)& = &I_{1}(t, S, G),\\ ^{FFM}_{0}D^{\xi,\lambda}_{t} R(t)& = &R_{1}(t, S, G). \end{eqnarray}$

Where

$\begin{eqnarray} S_{1}(t, S, G)& = &\textbf{a}-(\delta+\rho+\rho_{1})S,\\ E_{1}(t, S, G)& = &(\rho+\rho_{1})S-\delta E-\rho_{2}\alpha E V,\\ V_{1}(t, S, G)& = &\rho_{2}\alpha E V-(\delta+\mu_{0}+\omega-\textbf{b}+\phi)V,\\ I_{1}(t, S, G)& = &\phi V-(\mu_{0}+\delta+\psi)I,\\ R_{1}(t, S, G)& = &\omega V+\psi I-\delta R. \end{eqnarray}$

After using the fractal-fractional integral with the ML kernel, we obtain the following results:

$\begin{eqnarray} S(t_{\eta}+1)& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}S_{1}\left(t_{\eta},S(t_{\eta}),G(t_{\eta})\right)\\&&+ \frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\int_{t_{\nu}}^{t_{\nu+1}}S_{1}(t,S,G)\tau^{\xi-1}(t_{\eta+1} -\tau)^{\xi-1}{d}\tau,\\ E(t_{\eta}+1)& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}E_{1}\left(t_{\eta},S(t_{\eta}),G(t_{\eta})\right) \\&&+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\int_{t_{\nu}}^{t_{\nu+1}}E_{1}(t,S,G)\tau^{\xi-1}(t_{\eta+1} -\tau)^{\xi-1}{d}\tau,\\ V(t_{\eta}+1)& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}V_{1}\left(t_{\eta},S(t_{\eta}),G(t_{\eta})\right) \\&&+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\int_{t_{\nu}}^{t_{\nu+1}}V_{1}(t,S,G)\tau^{\xi-1}(t_{\eta+1} -\tau)^{\xi-1}{d}\tau,\\ I(t_{\eta}+1)& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}I_{1}\left(t_{\eta},S(t_{\eta}),G(t_{\eta})\right) \\&&+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\int_{t_{\nu}}^{t_{\nu+1}}I_{1}(t,S,G)\tau^{\xi-1}(t_{\eta+1} -\tau)^{\xi-1}{d}\tau,\\ R(t_{\eta}+1)& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}R_{1}\left(t_{\eta},S(t_{\eta}),G(t_{\eta})\right) \\&&+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\int_{t_{\nu}}^{t_{\nu+1}}R_{1}(t,S,G)\tau^{\xi-1}(t_{\eta+1} -\tau)^{\xi-1}{d}\tau, \end{eqnarray}$

(6.1)

where $G(t_{\eta}) = E(t_{\eta}), \, \, V(t_{\eta}), \, \, I(t_{\eta}), \, \, R(t_{\eta})$ .

Remember that the Newton polynomial can be obtained by using the Newton interpolation formula.

$\begin{eqnarray} N(t, S, G)&\simeq&N(t_{\eta-2},S_{\eta-2},G_{\eta-2})+\frac{1}{\Delta t}\Big[N(t_{\eta-1},S_{\eta-1},G_{\eta-1})\\ &-&N(t_{\eta-2},S_{\eta-2},G_{\eta-2})\Big]\left(\tau-t_{\eta-2}\right)+\frac{1}{2\Delta t^{2}}\Big[N(t_{\eta},S_{\eta},E_{\eta},I_{\eta},Q_{\eta},R_{\eta})\\ &-&2N(t_{\eta-1},S_{\eta-1},G_{\eta-1})-N(t_{\eta-2},S_{\eta-2},G_{\eta-2})\Big] \left(\tau-t_{\eta-2}\right)\left(\tau-t_{\eta-1}\right), \end{eqnarray}$

where $G_{\eta-2} = E_{\eta-2}, V_{\eta-2}, I_{\eta-2}, R_{\eta-2}$ , $G_{\eta-1} = E_{\eta-1}, V_{\eta-1}, I_{\eta-1}, R_{\eta-1}$ .

When we substitute the Newton polynomial into the system of Eqs (6.1), we obtain the following:

$\begin{eqnarray} S^{\eta+1}& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}S_{1}(t_{\eta},S(t_{\eta}),G(t_{\eta}))+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}S_{1} (t_{\nu-2},S^{\nu-2},G^{\nu-2})\\&&\times t^{\lambda-1}_{\nu-2} \int_{t_{\nu}}^{t_{\nu+1}}(t_{\eta+1}-\tau)^{\xi-1}{d}\tau +\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\frac{1}{\Delta t}\Big[t^{\lambda-1}_{\nu-1}S_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1}) \\&&-t^{\lambda-1}_{\nu-2} S_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau\\&&+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\frac{1}{2\Delta t^{2}}\Big[t^{\lambda-1}_{\nu}S_{1}(t_{\nu},S^{\nu},G^{\nu}) -2t^{\lambda-1}_{\nu-1}S_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\&&+t^{\lambda-1}_{\nu-2} S_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(\tau-t_{\nu-1})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau.\\ E^{\eta+1}& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}E_{1}(t_{\eta},S(t_{\eta}),G(t_{\eta}))+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}E_{1} (t_{\nu-2},S^{\nu-2},G^{\nu-2})\\&&\times t^{\lambda-1}_{\nu-2}\int_{t_{\nu}}^{t_{\nu+1}}(t_{\eta+1}-\tau)^{\xi-1}{d}\tau\ +\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\frac{1}{\Delta t}\Big[t^{\lambda-1}_{\nu-1}E_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\ &&-t^{\lambda-1}_{\nu-2} E_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau\\ &&+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\frac{1}{2\Delta t^{2}}\Big[t^{\lambda-1}_{\nu} E_{1}(t_{\nu},S^{\nu},G^{\nu}) -2t^{\lambda-1}_{\nu-1}E_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\&&+t^{\lambda-1}_{\nu-2} E_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(\tau-t_{\nu-1})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau.\\ V^{\eta+1}& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}V_{1}(t_{\eta},S(t_{\eta}),G(t_{\eta}))+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}V_{1} (t_{\nu-2},S^{\nu-2},G^{\nu-2})\\&&\times t^{\lambda-1}_{\nu-2}\int_{t_{\nu}}^{t_{\nu+1}}(t_{\eta+1}-\tau)^{\xi-1}{d}\tau +\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\frac{1}{\Delta t} \Big[t^{\lambda-1}_{\nu-1} V_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\ &&-t^{\lambda-1}_{\nu-2} V_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau\\&&+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\frac{1}{2\Delta t^{2}}\Big[t^{\lambda-1}_{\nu}V_{1}(t_{\nu},S^{\nu},G^{\nu}) -2t^{\lambda-1}_{\nu-1}V_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\&&+t^{\lambda-1}_{\nu-2} V_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(\tau-t_{\nu-1})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau.\\ I^{\eta+1}& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}I_{1}(t_{\eta},S(t_{\eta}),G(t_{\eta}))+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}I_{1} (t_{\nu-2},S^{\nu-2},G^{\nu-2})\\ &&\times t^{\lambda-1}_{\nu-2}\int_{t_{\nu}}^{t_{\nu+1}}(t_{\eta+1}-\tau)^{\xi-1}{d}\tau +\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\frac{1}{\Delta t}\Big[t^{\lambda-1}_{\nu-1} I_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\&&-t^{\lambda-1}_{\nu-2} I_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau\\ &&+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\frac{1}{2\Delta t^{2}}\Big[t^{\lambda-1}_{\nu}I_{1}(t_{\nu},S^{\nu},G^{\nu}) -2t^{\lambda-1}_{\nu-1}Q_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\&&+t^{\lambda-1}_{\nu-2} I_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(\tau-t_{\nu-1})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau.\\ R^{\eta+1}& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}R_{1}(t_{\eta},S(t_{\eta}),G(t_{\eta}))+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}R_{1} (t_{\nu-2},S^{\nu-2},G^{\nu-2})\\&&\times t^{\lambda-1}_{\nu-2}\int_{t_{\nu}}^{t_{\nu+1}}(t_{\eta+1} -\tau)^{\xi-1}{d}\tau\ +\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\frac{1}{\Delta t}\Big[t^{\lambda-1}_{\nu-1}R_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\ &&-t^{\lambda-1}_{\nu-2}R_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau\\ &&+\frac{\xi \lambda}{A B(\xi)\Gamma(\xi)}\sum^{\eta}_{\nu = 2}\frac{1}{2\Delta t^{2}}\Big[t^{\lambda-1}_{\nu}R_{1}(t_{\nu},S^{\nu},G^{\nu}) -2t^{\lambda-1}_{\nu-1}R_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\&&+t^{\lambda-1}_{\nu-2} R_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(\tau-t_{\nu-1})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau, \end{eqnarray}$

(6.2)

where $G^{\nu-2} = E^{\nu-2}, V^{\nu-2}, I^{\nu-2}, R^{\nu-2}$ , $G^{\nu-1} = E^{\nu-1}, V^{\nu-1}, I^{\nu-1}, R^{\nu-1}$ , $G^{\nu} = E^{\nu}, V^{\nu}, I^{\nu}, R^{\nu}$ , and $G(t_{\eta}) = E(t_{\eta}), V(t_{\eta}), I(t_{\eta}), R(t_{\eta})$ .

We can perform the following calculations for the integral in Eq (6.2):

$\begin{eqnarray} \int_{t_{\nu}}^{t_{\nu+1}}(t_{\eta+1}-\tau)^{\xi-1}{d}\tau& = &\frac{(\Delta t)^{\xi}}{\xi}\Big[(\eta-\nu+1)^{\xi}-(\eta-\nu)^{\xi}\Big],\\ \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau& = &\frac{(\Delta t)^{\xi+1}}{\xi(\xi+1)}\Big[(\eta-\nu+1)^{\xi}\\&&\times (\eta-\nu+3+2\xi)-(\eta-\nu)^{\xi}(\eta-\nu+3+3\xi)\Big].\\ \int_{t_{\nu}}^{t_{\nu+1}}(\tau-t_{\nu-2})(\tau-t_{\nu-1})(t_{\eta+1}-\tau)^{\xi-1}{d}\tau& = &\frac{(\Delta t)^{\xi+2}}{\xi(\xi+1)(\xi+2)}\Big[(\eta-\nu+1)^{\xi}\Big\{2(\eta-\nu)^{2}+(3\xi+10)\\&&\times(\eta-\nu)+2\xi^{2}+9\xi+12\Big\}-(\eta-\nu)^{\xi}\Big\{2(\eta-\nu)^{2}\\ &&+(5\xi+10)(\eta-\nu)+6\xi^{2}+18\xi+12\Big\}\Big], \end{eqnarray}$

(6.3)

substituting integral calculation values into Eq (6.2).

We acquire the numerical solutions $S(t), E(t), V(t), I(t)\, \, and \, \, R(t)$ :

$\begin{eqnarray} S^{\eta+1}& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}S_{1}(t_{\eta},S(t_{\eta}),G(t_{\eta})) +\frac{\xi \lambda(\Delta t)^{\xi}}{A B(\xi)\Gamma(\xi+1)}\sum^{\eta}_{\nu = 2} S_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\\&&\times t^{\lambda-1}_{\nu-2} \Big[(\eta-\nu+1)^{\xi}-(\eta-\nu)^{\xi}\Big]+\frac{\xi \lambda(\Delta t)^{\xi}}{A B(\xi)\Gamma(\xi+2)}\sum^{\eta}_{\nu = 2} \Big[t^{\lambda-1}_{\nu-1}S_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\&&- t^{\lambda-1}_{\nu-2}S_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \Big[(\eta-\nu+1)^{\xi}(\eta-\nu+3+2\xi)-(\eta-\nu)^{\xi}(\eta-\nu+3+3\xi)\Big]\\&&+\frac{\xi \lambda(\Delta t)^{\xi}}{2A B(\xi)\Gamma(\xi+3)}\sum^{\eta}_{\nu = 2}\Big[t^{\lambda-1}_{\nu}S_{1} (t_{\nu},S^{\nu},G^{\nu}) -2t^{\lambda-1}_{\nu-1}S_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\ &&+t^{\lambda-1}_{\nu-2}S_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \Big[(\eta-\nu+1)^{\xi}\Big\{2(\eta-\nu)^{2}+(3\xi+10)(\eta-\nu)+2\xi^{2}+9\xi+12\Big\}\\ &&-(\eta-\nu)^{\xi}\times\Big\{2(\eta-\nu)^{2}+(5\xi+10)(\eta-\nu)+6\xi^{2}+18\xi+12\Big\}\Big],\\ E^{\eta+1}& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}E_{1}(t_{\eta},S(t_{\eta}),G(t_{\eta})) +\frac{\xi \lambda(\Delta t)^{\xi}}{A B(\xi)\Gamma(\xi+1)}\sum^{\eta}_{\nu = 2} E_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\\&&\times t^{\lambda-1}_{\nu-2} \Big[(\eta-\nu+1)^{\xi}-(\eta-\nu)^{\xi}\Big]+\frac{\xi \lambda(\Delta t)^{\xi}}{A B(\xi)\Gamma(\xi+2)}\sum^{\eta}_{\nu = 2} \Big[t^{\lambda-1}_{\nu-1}E_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\ &&- t^{\lambda-1}_{\nu-2}E_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \Big[(\eta-\nu+1)^{\xi}(\eta-\nu+3+2\xi)-(\eta-\nu)^{\xi}(\eta-\nu+3+3\xi)\Big]\\ &&+\frac{\xi \lambda(\Delta t)^{\xi}}{2A B(\xi)\Gamma(\xi+3)}\sum^{\eta}_{\nu = 2}\Big[t^{\lambda-1}_{\nu}E_{1} (t_{\nu},S^{\nu},G^{\nu}) -2t^{\lambda-1}_{\nu-1}E_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\ &&+t^{\lambda-1}_{\nu-2}E_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \Big[(\eta-\nu+1)^{\xi}\Big\{2(\eta-\nu)^{2}+(3\xi+10)(\eta-\nu)+2\xi^{2}+9\xi+12\Big\}\\&&- (\eta-\nu)^{\xi}\times\Big\{2(\eta-\nu)^{2}+(5\xi+10)(\eta-\nu)+6\xi^{2}+18\xi+12\Big\}\Big],\\ V^{\eta+1}& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}V_{1}(t_{\eta},S(t_{\eta}),G(t_{\eta}))+\frac{\xi \lambda(\Delta t)^{\xi}}{A B(\xi)\Gamma(\xi+1)}\sum^{\eta}_{\nu = 2} V_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\\&&\times t^{\lambda-1}_{\nu-2} \Big[(\eta-\nu+1)^{\xi}-(\eta-\nu)^{\xi}\Big]+\frac{\xi \lambda(\Delta t)^{\xi}}{A B(\xi)\Gamma(\xi+2)}\sum^{\eta}_{\nu = 2} \Big[t^{\lambda-1}_{\nu-1}V_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\&&- t^{\lambda-1}_{\nu-2}V_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \Big[(\eta-\nu+1)^{\xi}(\eta-\nu+3+2\xi)-(\eta-\nu)^{\xi}(\eta-\nu+3+3\xi)\Big]\\ &&+\frac{\xi \lambda(\Delta t)^{\xi}}{2A B(\xi)\Gamma(\xi+3)}\sum^{\eta}_{\nu = 2}\Big[t^{\lambda-1}_{\nu}V_{1} (t_{\nu},S^{\nu},G^{\nu}) -2t^{\lambda-1}_{\nu-1}V_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\ &&+t^{\lambda-1}_{\nu-2}V_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \Big[(\eta-\nu+1)^{\xi}\Big\{2(\eta-\nu)^{2}+(3\xi+10)(\eta-\nu)+2\xi^{2}+9\xi+12\Big\}\\&&- (\eta-\nu)^{\xi}\times\Big\{2(\eta-\nu)^{2}+(5\xi+10)(\eta-\nu)+6\xi^{2}+18\xi+12\Big\}\Big],\\ I^{\eta+1}& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}I_{1}(t_{\eta},S(t_{\eta}),G(t_{\eta})) +\frac{\xi \lambda(\Delta t)^{\xi}}{A B(\xi)\Gamma(\xi+1)}\sum^{\eta}_{\nu = 2} I_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\\&&\times t^{\lambda-1}_{\nu-2} \Big[(\eta-\nu+1)^{\xi}-(\eta-\nu)^{\xi}\Big]+\frac{\xi \lambda(\Delta t)^{\xi}}{A B(\xi)\Gamma(\xi+2)}\sum^{\eta}_{\nu = 2} \Big[t^{\lambda-1}_{\nu-1}I_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\ &&-t^{\lambda-1}_{\nu-2}I_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \Big[(\eta-\nu+1)^{\xi}(\eta-\nu+3+2\xi)-(\eta-\nu)^{\xi}(\eta-\nu+3+3\xi)\Big]\\&&+\frac{\xi \lambda(\Delta t)^{\xi}}{2A B(\xi)\Gamma(\xi+3)}\sum^{\eta}_{\nu = 2}\Big[t^{\lambda-1}_{\nu}I_{1} (t_{\nu},S^{\nu},G^{\nu}) -2t^{\lambda-1}_{\nu-1}I_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\ &&+t^{\lambda-1}_{\nu-2}I_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \Big[(\eta-\nu+1)^{\xi}\Big\{2(\eta-\nu)^{2}+(3\xi+10)(\eta-\nu)+2\xi^{2}+9\xi+12\Big\}\\ &&-(\eta-\nu)^{\xi}\times\Big\{2(\eta-\nu)^{2}+(5\xi+10)(\eta-\nu)+6\xi^{2}+18\xi+12\Big\}\Big],\\ R^{\eta+1}& = &\frac{\lambda(1-\xi)}{A B(\xi)}t_{\eta}^{\lambda-1}R_{1}(t_{\eta},S(t_{\eta}),G(t_{\eta}))+\frac{\xi \lambda(\Delta t)^{\xi}}{A B(\xi)\Gamma(\xi+1)}\sum^{\eta}_{\nu = 2} R_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\\&&\times t^{\lambda-1}_{\nu-2} \Big[(\eta-\nu+1)^{\xi}-(\eta-\nu)^{\xi}\Big]+\frac{\xi \lambda(\Delta t)^{\xi}}{A B(\xi)\Gamma(\xi+2)}\sum^{\eta}_{\nu = 2} \Big[t^{\lambda-1}_{\nu-1}R_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\&&- t^{\lambda-1}_{\nu-2}R_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \Big[(\eta-\nu+1)^{\xi}(\eta-\nu+3+2\xi)-(\eta-\nu)^{\xi}(\eta-\nu+3+3\xi)\Big]\\ &&+\frac{\xi \lambda(\Delta t)^{\xi}}{2 A B(\xi)\Gamma(\xi+3)}\sum^{\eta}_{\nu = 2}\Big[t^{\lambda-1}_{\nu}R_{1} (t_{\nu},S^{\nu},G^{\nu}) -2t^{\lambda-1}_{\nu-1}R_{1}(t_{\nu-1},S^{\nu-1},G^{\nu-1})\\ &&+t^{\lambda-1}_{\nu-2}R_{1}(t_{\nu-2},S^{\nu-2},G^{\nu-2})\Big] \Big[(\eta-\nu+1)^{\xi}\Big\{2(\eta-\nu)^{2}+(3\xi+10)(\eta-\nu)+2\xi^{2}+9\xi+12\Big\}\\&&-(\eta-\nu)^{\xi}\times\Big\{2(\eta-\nu)^{2}+(5\xi+10)(\eta-\nu)+6\xi^{2}+18\xi+12\Big\}\Big]. \end{eqnarray}$

7. Simulation explanation

In this section, we utilized an advanced technique to obtain theoretical outcomes and assess their effectiveness. The newly developed SEVIR system was analyzed through simulation. By applying non-integer parametric values in the SARS-COVID-19 model, we obtained interesting findings. – display the solutions for $S(t)$ , $E(t)$ , $V(t)$ , $I(t)$ , and $R(t)$ by reducing the fractional values to the desired level. To validate the efficiency of the theoretical outcomes, we provide the following examples. Numerical simulations for the SARS-COVID-19 model were performed using MATLAB. The initial conditions used in the newly developed model are $S(0) = 217.342565, E(0) = 100, V(0) = 1.386348, I(0) = 1.1$ and $R(0) = 1.271087$ . The parameter values used in the developed system are as follows: $\textbf{a} = 1.43$ , $\delta = 0.000065$ , $\rho = 0.45$ , $\rho_{1} = 0.10$ , $\rho_{2} = 0.020$ , $\alpha = 0.0008601$ , $\mu_{0} = 0.19$ , $\omega = 0.98$ , $\textbf{b} = 0.135$ , $\phi = 0.0001$ , and $\psi = 0.0001$ . Figures 2, 4, and 5 illustrate the changes in susceptible, vaccinated, and infected individuals respectively, showing a sharp decrease before reaching a stable position. Meanwhile, Figures 3 and 6 demonstrate the dynamics of exposed and recovered individuals respectively at different fractional orders in which both individuals increases and after certain time the number of individuals approaches stable state using different dimensions. The research predicts future infection rates and suggests ways to decrease the spread of infection units more effectively. By utilizing a fractal-fractional approach, the study yields reliable and accurate results for all compartments at non-integer order derivatives, which are more trustworthy when fractional values are reduced as well a by reducing its dimensions. The findings suggest that the number of infected individuals decreases significantly due to vaccination measures, while the number of recovered individuals increases due to a decline in infected individuals and the effect of vaccination.

Figure 2. The value of

$S(t)$ using the fractal-fractional operator with various fractional values at different dimensions.

DownLoad: Full-Size Img PowerPoint

Figure 3. The value of

$E(t)$ using the fractal-fractional operator with various fractional values at different dimensions.

DownLoad: Full-Size Img PowerPoint

Figure 4. The value of

$V(t)$ using the fractal-fractional operator with various fractional values at different dimensions.

DownLoad: Full-Size Img PowerPoint

Figure 5. The value of

$I(t)$ using the fractal-fractional operator with various fractional values at different dimensions.

DownLoad: Full-Size Img PowerPoint

Figure 6. The value of

$R(t)$ using the fractal-fractional operator with various fractional values at different dimensions.

DownLoad: Full-Size Img PowerPoint

8. Conclusions

This article employs a fractional order SEVIR model for SARS-COVID-19 with vaccinated effects using an FFO to find reliable solutions. We provide advice on controlling this virus to help our community overcome the pandemic by implementing vaccinated measures for low immune individuals. We analyze the dangerous coronavirus disease with the effect of vaccination to understand its real impact on the community. Qualitative and quantitative analyses are conducted to verify its stable position in a continuous dynamical system. We also verify that the fractional order coronavirus disease model has bounded and unique solutions. We examine the impact of global measures to control the spread of the coronavirus disease. Also, analyses are performed to see how the rate of infection changes after the implementation of vaccination measures. We ensure that our findings are reliable and realistic. FFO is used for continuously monitoring the spread as well as control of the disease in society after vaccination measures. It was observed that infected individuals recover quickly due to the vaccinated strategy. The fractal-fractional operator (FFO) is used for continuously monitoring for the spread of the diseases using different fractional values as well as reliable solutions. In fractal-fractional operators, fractal represents the dimensions of the spread of the disease, and fractional represents the fractional ordered derivative operator which provides the real behavior of the spread as well as control of COVID-19 with different dimensions and continuous monitoring, which can be observed in simulation. We conduct numerical simulations to observe how the disease controlled in the community after the implementation of vaccination measures using different fractional values with different dimensions. Additionally, future estimates are provided based on our findings, which can help in mitigating the risk of the disease spreading in the environment.

Use of AI tools declaration

The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

Acknowledgments

The authors would like to extend their sincere appreciation to Researchers Supporting Project number (RSP2024R472), King Saud University, Riyadh, Saudi Arabia.

Conflict of interest

All authors declare no conflicts of interest in this paper.

References

[1]	E. Domingo, Mechanisms of viral emergence, Vet. Res., 41 (2010), 38. https://doi.org/10.1051/vetres/2010010 doi: 10.1051/vetres/2010010
[2]	S. T. Nichol, J. Arikawa, Y. Kawaoka, Emerging viral diseases, Proc. Natl. Acad. Sci., 97 (2000), 12411–12412. https://doi.org/10.1073/pnas.210382297 doi: 10.1073/pnas.210382297
[3]	Q. Abid, T. Nishant, T. Himani, K. Manoj, AVPdb: a database of experimentally validated antiviral peptides targeting medically important viruses, Nucleic Acids Res., 42 (2014), D1147–D1153. https://doi.org/10.1093/nar/gkt1191 doi: 10.1093/nar/gkt1191
[4]	T. Phan. Genetic diversity and evolution of SARS-CoV2, Infect. Genet. Evol., 81 (2020), 104260. https://doi.org/10.1016/j.meegid.2020.104260 doi: 10.1016/j.meegid.2020.104260
[5]	E. Sherif, A. Maha, The potential of antimicrobial peptides as an antiviral therapy against COVID-19, ACS Pharmacol. Transl. Sci., 3 (2020), 780–782. https://doi.org/10.1021/acsptsci.0c00059 doi: 10.1021/acsptsci.0c00059
[6]	T. Uhlig, T. Kyprianou, F. G. Martinelli, C. A. Oppici, D. Heiligers, D. Hills, et al., The emergence of peptides in the pharmaceutical business: From exploration to exploitation, EuPA Open Proteomics, 4 (2014), 58–69. https://doi.org/10.1016/j.euprot.2014.05.003 doi: 10.1016/j.euprot.2014.05.003
[7]	L. Otvos, Peptide-based drug design: here and now, Methods Mol. Biol., 494 (2008), 1–8. https://doi.org/10.1007/978-1-59745-419-3 doi: 10.1007/978-1-59745-419-3
[8]	R. E. W. Hancock, H. G. Sahl, Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies, Nat. Biotechnol., 24 (2006), 1551–1557. https://doi.org/10.1038/nbt1267 doi: 10.1038/nbt1267
[9]	A, Furka, F. Sebestyén, M. Asgedom, G. Dibó, General method for rapid synthesis of multicomponent peptide mixtures, Int. J. Pept. Protein Res., 37 (1991), 487–493. https://doi.org/10.1111/j.1399-3011.1991.tb00765.x doi: 10.1111/j.1399-3011.1991.tb00765.x
[10]	K. Bozovičar, T. Bratkovič, Evolving a peptide: library platforms and diversification strategies, Int. J. Mol. Sci., 21 (2019), 215. https://doi.org/10.3390/ijms21010215 doi: 10.3390/ijms21010215
[11]	Z. Y. Lou, Y. N. Sun, Z. H. Rao, Current progress in antiviral strategies. Trends Pharmacol. Sci., 35 (2014), 86–102. https://doi.org/10.1016/j.tips.2013.11.006 doi: 10.1016/j.tips.2013.11.006
[12]	F. Yu, L. Lu, L. Y. Du, X. J. Zhu, A. K. Debnath, S. Jiang, Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket, Viruses, 5 (2013), 127–149. https://doi.org/10.3390/v5010127 doi: 10.3390/v5010127
[13]	C. K. McDonald, D. R. Kuritzkes, Human immunodeficiency virus type 1 protease inhibitors, Arch. Intern. Med., 157 (1997), 951–959.
[14]	J. J. Kiser, C. Flexner, Direct-acting antiviral agents for hepatitis C virus infection, Annu. Rev. Pharmacol. Toxicol., 53 (2013), 427–449. https://doi.org/10.1146/annurev-pharmtox-011112-140254 doi: 10.1146/annurev-pharmtox-011112-140254
[15]	R. Eléonore, R. Jean-Christophe, B. Véronique, J. Corinne, P. Pierre, T, Noël, et al., Antiviral drug discovery strategy using combinatorial libraries of structurally constrained peptides, J. Virol., 78 (2004), 7410–7417. https://doi.org/10.1128/JVI.78.14.7410-7417.2004 doi: 10.1128/JVI.78.14.7410-7417.2004
[16]	G. Castel, M. Chtéoui, B. Heyd, N. Tordo, Phage display of combinatorial peptide libraries: application to antiviral research, Molecules, 16 (2011), 3499–3518. https://doi.org/10.3390/molecules16053499 doi: 10.3390/molecules16053499
[17]	M. F. Chew, K. S. Poh, C. L. Poh, Peptides as therapeutic agents for dengue virus, Int. J. Med. Sci., 14 (2017), 1342–1359. https://doi.org/10.7150/ijms.21875. doi: 10.7150/ijms.21875
[18]	S. Saheli, Vaccination: the present and the future, Yale J. Biol. Med., 84 (2011), 353–359.
[19]	H. B. Jiang, Y. D. Xu, L. Li, L. Y. Weng, Q. Wang, S. J. Zhang, et al., Inhibition of influenza virus replication by constrained peptides targeting nucleoprotein, Antiviral Chem. Chemother., 22 (2011), 119–130. https://doi.org/10.3851/IMP1902 doi: 10.3851/IMP1902
[20]	T. Nishant, Q. Abid, K. Manoj, AVPpred: collection and prediction of highly effective antiviral peptides, Nucleic Acids Res., 40 (2012), W199–W204. https://doi.org/10.1093/nar/gks450 doi: 10.1093/nar/gks450
[21]	K. Y. Chang, J. R. Yang, Analysis and prediction of highly effective antiviral peptides based on random forests, PloS One, 8 (2013), e70166. https://doi.org/10.1371/journal.pone.0070166 doi: 10.1371/journal.pone.0070166
[22]	M. Zare, H. Mohabatkar, F. K. Faramarzi, M. M. Beigi, M. Behbahani, Using Chou's pseudo amino acid composition and machine learning method to predict the antiviral peptides, Open Bioinf. J., 9 (2015), 13–19. https://doi.org/10.2174/1875036201509010013 doi: 10.2174/1875036201509010013
[23]	B. F. J. Lissabet, H. L. Belén, G. J. Farias, AntiVPP 1.0: A portable tool for prediction of antiviral peptides, Comput. Biol. Med., 107 (2019), 127–130. https://doi.org/10.1016/j.compbiomed.2019.02.011 doi: 10.1016/j.compbiomed.2019.02.011
[24]	N. Schaduangrat, C. Nantasenamat, V. Prachayasittikul, W. Shoombuatong, Meta-iAVP: a sequence-based meta-predictor for improving the prediction of antiviral peptides using effective feature representation, Int. J. Mol. Sci., 20 (2019), 5743. https://doi.org/10.3390/ijms20225743 doi: 10.3390/ijms20225743
[25]	S. C. Abu, M. R. Sarah, K. H. Kylene, B. Barney, M. W. R. Bobbie-Jo, Better understanding and prediction of antiviral peptides through primary and secondary structure feature importance, Sci. Rep., 10 (2020), 19260. https://doi.org/10.1038/s41598-020-76161-8 doi: 10.1038/s41598-020-76161-8
[26]	J. W. Li, Y. Q. Pu, J. J. Tang, Q. Zou, F. Guo, DeepAVP: a dual-channel deep neural network for identifying variable-length antiviral peptides, IEEE J. Biomed. Health, 24 (2020), 3012–3019. https://doi.org/10.1109/JBHI.2020.2977091 doi: 10.1109/JBHI.2020.2977091
[27]	Y. X. Pang, Z. Wang, J. H. Jhong, T. Y. Lee, Identifying anti-coronavirus peptides by incorporating different negative datasets and imbalanced learning strategies, Briefings Bioinf., 22 (2021), 1085–1095. https://doi.org/10.1093/bib/bbaa423 doi: 10.1093/bib/bbaa423
[28]	Y. Pang, L. Yao, J. H. Jhong, Z. Wang, T. Y. Lee, AVPIden: a new scheme for identification and functional prediction of antiviral peptides based on machine learning approaches, Brief. Bioinform., 22 (2021), bbab263. https://doi.org/10.1093/bib/bbab263 doi: 10.1093/bib/bbab263
[29]	P. B. Timmons, C. M. Hewage, ENNAVIA is a novel method which employs neural networks for antiviral and anti-coronavirus activity prediction for therapeutic peptides, Briefings Bioinf., 22 (2021), bbab258. https://doi.org/10.1093/bib/bbab258 doi: 10.1093/bib/bbab258
[30]	G. Agarwal, R. Gabrani, Antiviral peptides: identification and validation, Int. J. Pept. Res. Ther., 27 (2021), 149–168. https://doi.org/10.1007/s10989-020-10072-0 doi: 10.1007/s10989-020-10072-0
[31]	P. Charoenkwan, N. Anuwongcharoen, C. Nantasenamat, M. M. Hasan, W. Shoombuatong, In silico approaches for the prediction and analysis of antiviral peptides: a review, Curr. Pharm. Design, 27 (2021), 2180–2188. https://doi.org/10.2174/1381612826666201102105827 doi: 10.2174/1381612826666201102105827
[32]	B. Manavalan, S. Basith, G. Lee, Comparative analysis of machine learning-based approaches for identifying therapeutic peptides targeting SARS-CoV-2, Briefings Bioinf., 23 (2022), bbab412. https://doi.org/10.1093/bib/bbab412 doi: 10.1093/bib/bbab412
[33]	H. Kurata, S. Tsukiyama, B. Manavalan, iACVP: markedly enhanced identification of anti-coronavirus peptides using a dataset-specific word2vec model, Briefings Bioinf., 23 (2022), bbac265. https://doi.org/10.1093/bib/bbac265 doi: 10.1093/bib/bbac265
[34]	M. K. Pirtskhalava, A. A. Amstrong, M. Grigolava, M. Chubinidze, E. Alimbarashvili, B. M. Vishnepolsky, DBAASP v3: database of antimicrobial/cytotoxic activity and structure of peptides as a resource for development of new therapeutics, Nucleic. Acids Res., 49 (2021), D288–D297. https://doi.org/10.1093/nar/gkaa991 doi: 10.1093/nar/gkaa991
[35]	F. H. Waghu, L. Gopi, R. S. Barai, P. Ramteke, B. Nizami, S. Idicula-Thomas, CAMP: Collection of sequences and structures of antimicrobial peptides, Nucleic. Acids Res., 42 (2014), D1154–D1158. https://doi.org/10.1093/nar/gkt1157 doi: 10.1093/nar/gkt1157
[36]	G. S. Wang, X. Li, Z. Wang, APD3: the antimicrobial peptide database as a tool for research and education, Nucleic. Acids Res., 44 (2016), D1087–D1093. https://doi.org/10.1093/nar/gkv1278 doi: 10.1093/nar/gkv1278
[37]	S. Lata, N. K. Mishra, G. P. S. Raghava, AntiBP2: improved version of antibacterial peptide prediction, BMC Bioinf., 11 (2010), S19. https://doi.org/10.1186/1471-2105-11-S1-S19 doi: 10.1186/1471-2105-11-S1-S19
[38]	N. Bupi, V. K. Sangaraju, L. T. Phan, A. Lal, T. T. B. Vo, P. T. Ho, et al., An effective integrated machine learning framework for identifying severity of tomato yellow leaf curl virus and their experimental validation, Research, 6 (2023), 16. https://doi.org/10.34133/research.0016 doi: 10.34133/research.0016
[39]	H. Y. Shi, S. L. Zhang, Accurate prediction of anti-hypertensive peptides based on convolutional neural network and gated recurrent unit, Interdiscip. Sci., 14 (2022), 879–894. https://doi.org/10.1007/s12539-022-00521-3 doi: 10.1007/s12539-022-00521-3
[40]	S. L. Zhang, X. J. Li, Pep-CNN: An improved convolutional neural network for predicting therapeutic peptides, Chemometr. Intell. Lab., 221 (2022), 104490. https://doi.org/10.1016/j.chemolab.2022.104490 doi: 10.1016/j.chemolab.2022.104490
[41]	M. M. Hasan, Y. Zhou, X. T. Lu, J. Y. Li, J. N. Song, Z. D. Zhang, Computational identification of protein pupylation sites by using profile-based composition of k-spaced amino acid pairs, PloS One, 10 (2015), e0129635. https://doi.org/10.1371/journal.pone.0129635 doi: 10.1371/journal.pone.0129635
[42]	Z. Ju, J. Z. Cao, Prediction of protein N-formylation using the composition of k-spaced amino acid pairs, Anal. Biochem., 534 (2017), 40–45. https://doi.org/10.1016/j.ab.2017.07.011 doi: 10.1016/j.ab.2017.07.011
[43]	Z. Ju, S. Y. Wang, Prediction of lysine formylation sites using the composition of k-spaced amino acid pairs via Chou's 5-steps rule and general pseudo components, Genomics, 112 (2020), 859–866. https://doi.org/10.1016/j.ygeno.2019.05.027 doi: 10.1016/j.ygeno.2019.05.027
[44]	M. M. Hasan, M. S. Khatun, M. N. H. Mollah, Y. Cao, D. J. Guo, NTyroSite: Computational identification of protein nitrotyrosine sites using sequence evolutionary features, Molecules, 23 (2018), 1667. https://doi.org/10.3390/molecules23071667 doi: 10.3390/molecules23071667
[45]	H. L. Fu, Y. X. Yang, X. B. Wang, H. Wang, Y. Xu, DeepUbi: a deep learning framework for prediction of ubiquitination sites in proteins, BMC Bioinf., 20 (2019), 86. https://doi.org/10.1186/s12859-019-2677-9 doi: 10.1186/s12859-019-2677-9
[46]	J. N. Song, Y. N. Wang, F. Y. Li, T. Akutsu, N. D. Rawlings, G. I. Webb, K. C. Chou, iProt-Sub: a comprehensive package for accurately mapping and predicting protease-specific substrates and cleavage sites, Briefings Bioinf., 20 (2019), 638–658. https://doi.org/10.1093/bib/bby028 doi: 10.1093/bib/bby028
[47]	M. Usman, S. Khan, J. A. Lee, Afp-lse: Antifreeze proteins prediction using latent space encoding of composition of k-spaced amino acid pairs, Sci. Rep., 10 (2020), 7197. https://doi.org/10.1038/s41598-020-63259-2 doi: 10.1038/s41598-020-63259-2
[48]	Z. Chen, P. Zhao, F. Y. Li, A. Leier, T. T. Marquez-Lago, Y. N. Wang, et al., iFeature: a python package and web server for features extraction and selection from protein and peptide sequences, Bioinformatics, 34 (2018), 2499–2502. https://doi.org/10.1093/bioinformatics/bty140 doi: 10.1093/bioinformatics/bty140
[49]	Y. Zhu, C. Z. Jia, F. Y. Li, J. N. Song, Inspector: a lysine succinylation predictor based on edited nearest-neighbor undersampling and adaptive synthetic oversampling, Anal. Biochem., 593 (2020), 113592. https://doi.org/10.1016/j.ab.2020.113592 doi: 10.1016/j.ab.2020.113592
[50]	C. R. Chung, T. R. Kuo, L. C. Wu, T. Y. Lee, J. T. Horng, Characterization and identification of antimicrobial peptides with different functional activities, Briefings Bioinf., 21 (2020), 1098–1114. https://doi.org/10.1093/bib/bbz043 doi: 10.1093/bib/bbz043
[51]	Y. J. Wang, Q. Zhang, M. A. Sun, D. J. Guo, High-accuracy prediction of bacterial type Ⅲ secreted effectors based on position specific amino acid composition profiles, Bioinformatics, 27 (2011), 777–784. https://doi.org/10.1093/bioinformatics/btr021 doi: 10.1093/bioinformatics/btr021
[52]	T. Y. Lee, Z. Q. Lin, S. J. Hsieh, N. A. Bretana, C. T. Lu, Exploiting maximal dependence decomposition to identify conserved motifs from a group of aligned signal sequences, Bioinformatics, 27 (2011), 1780–1787. https://doi.org/10.1093/bioinformatics/btr291 doi: 10.1093/bioinformatics/btr291
[53]	X. Y. Wang, B. Yu, A. J. Ma, C. Chen, B. Q. Liu, Q. Ma, Protein-protein interaction sites prediction by ensemble random forests with synthetic minority oversampling technique, Bioinformatics, 35 (2019), 2395–2402. https://doi.org/10.1093/bioinformatics/bty995 doi: 10.1093/bioinformatics/bty995
[54]	B. G. Tian, X. Wu, C. Chen, W. Y. Qiu, Q. Ma, B. Yu, Predicting protein-protein interactions by fusing various Chou's pseudo components and using wavelet denoising approach, J. Theor. Biol., 462 (2019), 329–346. https://doi.org/10.1016/j.jtbi.2018.11.011 doi: 10.1016/j.jtbi.2018.11.011
[55]	Z. H. Zhang, Z. H. Wang, Z. R. Zhang, Y. X. Wang, A novel method for apoptosis protein subcellular localization prediction combining encoding based on grouped weight and support vector machine, FEBS Lett., 580 (2006), 6169–6174. https://doi.org/10.1016/j.febslet.2006.10.017 doi: 10.1016/j.febslet.2006.10.017
[56]	I. Dubchak, I. Muchnik, S. R. Holbrook, S. H. Kim, Prediction of protein folding class using global description of amino acid sequence, Proc. Natl. Acad. Sci., 92 (1995), 8700–8704. https://doi.org/10.2307/2368330 doi: 10.2307/2368330
[57]	Z. R. Li, H. H. Lin, L. Y. Han, L. Jiang, X. Chen, Y. Z. Chen, PROFEAT: a web server for computing structural and physicochemical features of proteins and peptides from amino acid sequence, Nucleic. Acids Res., 34 (2006), W32–W37. https://doi.org/10.1093/nar/gkl305 doi: 10.1093/nar/gkl305
[58]	H. Lv, F. Y. Dao, Z. X. Guan, H. Yang, Y. W. Li, H. Lin, Deep-Kcr: accurate detection of lysine crotonylation sites using deep learning method, Briefings Bioinf., 22 (2021), bbaa255. https://doi.org/10.1093/bib/bbaa255 doi: 10.1093/bib/bbaa255
[59]	S. Hochreiter, J. Schmidhuber, Long short-term memory, Neural Comput., 9 (1997), 1735–1780. https://doi.org/10.1162/neco.1997.9.8.1735 doi: 10.1162/neco.1997.9.8.1735
[60]	A. Graves, J. Schmidhuber, Framewise phoneme classification with bidirectional LSTM and other neural network architectures, Neural Networks, 18 (2005), 602–610. https://doi.org/10.1016/j.neunet.2005.06.042 doi: 10.1016/j.neunet.2005.06.042
[61]	J. W. Li, Y. Q. Pu, J. J. Tang, Q. Zou, F. Guo, DeepATT: a hybrid category attention neural network for identifying functional effects of DNA sequences, Briefings Bioinf., 22 (2021), bbaa159. https://doi.org/10.1093/bib/bbaa159 doi: 10.1093/bib/bbaa159
[62]	K. M. He, X. Y. Zhang, S. Q. Ren, J. Sun, Deep residual learning for image recognition, Comput. Sci., (2016), 770–778. https://doi.org/10.48550/arXiv.1512.03385 doi: 10.48550/arXiv.1512.03385
[63]	R. Zhou, X. Q. Hu, B. Yuan, Q. W. Xu, Lithology classification system for well logging based on bidirectional gated recurrent unit, in 2021 4th International conference on artificial intelligence and big data (ICAIBD), (2021), 599–603. https://doi.org/10.1109/ICAIBD51990.2021.9459000
[64]	S. L. Zhang, Y. Y. Jing, PreVFs-RG: A deep hybrid model for identifying virulence factors based on residual block and gated recurrent unit, IEEE/ACM Trans. Comput. Biol. Bioinf., 20 (2022), 1926–1934. https://doi.org/10.1109/TCBB.2022.3223038 doi: 10.1109/TCBB.2022.3223038
[65]	K. M. He, X. Y. Zhang, S. Q. Ren, J. Sun, Identity mappings in deep residual networks, in Computer Vision–ECCV 2016: 14th European Conference, (2016), 630–645. https://doi.org/10.48550/arXiv.1603.05027
[66]	K. Cho, B. V. Merrienboer, C. Gulcehre, D. Bahdanau, F. Bougares, H. Schwenk, et al., Learning phrase representations using RNN encoder-decoder for statistical machine translation, preprint, arXiv: 1406.1078. https://doi.org/10.48550/arXiv.1406.1078
[67]	K. Abdelli, J. Y. Cho, F. Azendorf, H. Griesser, C. Tropschug, S. Pachnicke, Machine-learning-based anomaly detection in optical fiber monitoring, J. Opt. Commun. Networking, 14 (2022), 365–375. https://doi.org/10.1364/JOCN.451289 doi: 10.1364/JOCN.451289
[68]	Q. H. Kha, Q. T. Ho, N. Q. K. Le, Identifying SNARE proteins using an alignment-free method based on multiscan convolutional neural network and PSSM profiles, J. Chem. Inf. Model., 62 (2022), 4820–4826. https://doi.org/10.1021/acs.jcim.2c01034 doi: 10.1021/acs.jcim.2c01034
[69]	N. Q. K. Le, T. T. D. Nguyen, Y. Y. Ou, Identifying the molecular functions of electron transport proteins using radial basis function networks and biochemical properties, J. Mol. Graph. Model., 73 (2017), 166–178. https://doi.org/10.1016/j.jmgm.2017.01.003 doi: 10.1016/j.jmgm.2017.01.003
[70]	W. Shoombuatong, S. Basith, T. Pitti, G. Lee, B. Manavalan, THRONE: a new approach for accurate prediction of human RNA N7-methylguanosine sites, J. Mol. Biol., 434 (2022), 167549. https://doi.org/10.1016/j.jmb.2022.167549 doi: 10.1016/j.jmb.2022.167549
[71]	L. Y. Wei, W. J. He, A. Malik, R. Su, L. Z. Cui, B. Manavalan, Computational prediction and interpretation of cell-specific replication origin sites from multiple eukaryotes by exploiting stacking framework, Briefings Bioinf., 22 (2021), bbaa275. https://doi.org/10.1093/bib/bbaa275 doi: 10.1093/bib/bbaa275
[72]	M. M. Hasan, S. Tsukiyama, J. Y. Cho, H. Kurata, M. A. Alam, X. W. Liu, et al., Deepm5C: a deep-learning-based hybrid framework for identifying human RNA N5-methylcytosine sites using a stacking strategy, Mol. Ther., 30 (2022), 2856–2867. https://doi.org/10.1016/j.ymthe.2022.05.001 doi: 10.1016/j.ymthe.2022.05.001
[73]	P. Charoenkwan, W. Chiangjong, C. Nantasenamat, M. M. Hasan, B. Manavalan, W. Shoombuatong, StackIL6: a stacking ensemble model for improving the prediction of IL-6 inducing peptides, Briefings Bioinf., 22 (2021), bbab172. https://doi.org/10.1093/bib/bbab172 doi: 10.1093/bib/bbab172
[74]	V. Vacic, L. M. Iakoucheva, P. Radivojac, Two Sample Logo: a graphical representation of the differences between two sets of sequence alignments, Bioinformatics, 22 (2006), 1536–1537. https://doi.org/10.1093/bioinformatics/btl151 doi: 10.1093/bioinformatics/btl151
[75]	M. Y. Liu, H. M. Liu, T. Wu, Y. X. Zhu, Y. W. Zhou, Z. R. Huang, et al., ACP‑Dnnel: anti‑coronavirus peptides' prediction based on deep neural network ensemble learning, Amino Acids, 55 (2023), 1121–1136. https://doi.org/10.1007/s00726-023-03300-6 doi: 10.1007/s00726-023-03300-6

This article has been cited by:

1.	Kottakkaran Sooppy Nisar, Muhammad Owais Kulachi, Aqeel Ahmad, Muhammad Farman, Muhammad Saqib, Muhammad Umer Saleem, Fractional order cancer model infection in human with CD8+ T cells and anti-PD-L1 therapy: simulations and control strategy, 2024, 14, 2045-2322, 10.1038/s41598-024-66593-x
2.	Muhammad Owais Kulachi, Aqeel Ahmad, Evren Hincal, Ali Hasan Ali, Muhammad Farman, Muhammad Taimoor, Control of conjunctivitis virus with and without treatment measures: A bifurcation analysis, 2024, 36, 10183647, 103273, 10.1016/j.jksus.2024.103273
3.	Faisal Javed, Aqeel Ahmad, Ali Hasan Ali, Evren Hincal, Ayesha Amjad, Investigation of conjunctivitis adenovirus spread in human eyes by using bifurcation tool and numerical treatment approach, 2024, 99, 0031-8949, 085253, 10.1088/1402-4896/ad62a5
4.	Kottakkaran Sooppy Nisar, Aqeel Ahmad, Muhammad Farman, Evren Hincal, Anum Zehra, Modeling and mathematical analysis of fractional order Eye infection (conjunctivitis) virus model with treatment impact: Prelicence and dynamical transmission, 2024, 107, 11100168, 33, 10.1016/j.aej.2024.07.020
5.	Khadija Khatun, Md. Mamun-Ur-Rashid Khan, Jun Tanimoto, Aspiration can decline epidemic disease, 2025, 112, 11100168, 151, 10.1016/j.aej.2024.10.087
6.	Aqeel Ahmad, Muhammad Owais Kulachi, Ayman A. Aly, Mustafa Inc, M.O. Ahmad, Shahram Rezapour, Flip bifurcation analysis and investigation of conjunctivitis virus by using sustainable control approach, 2025, 100, 17468094, 106956, 10.1016/j.bspc.2024.106956

Reader Comments

Your name:*

Email:*
© 2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)